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V. CHAPTER ONE 
 
Introduction 
 15 
1. Diabetic neuropathy 
Diabetes Mellitus 
Diabetes mellitus (DM) encompasses multiple metabolic disorders that are 
ultimately associated with hyperglycemia. In 2007, 23.6 million Americans (7.8% of 
the population) were affected with one form of diabetes while an estimated 5.7 
million Americans were undiagnosed (National Institute of Diabetes and Digestive 
and Kidney Diseases (NIDDK), 2007). The figures from 2007 were increased by 2.6 
million people compared to reports from only two years ago (CDC, 2005). In 2002, it 
was estimated that diabetes cost the United States approximately $132 billion when 
medical expenses and the price of lost productivity were combined (Hogan et al., 
2003). Moreover, the figure from 2002 was likely underestimated as patients with 
diabetes also have greater contact with other healthcare-related providers such as 
optometrists, dentists, etc. In addition, recent reports estimate that in 2007 the direct 
and indirect costs of diabetes in the United States had increased to $174 billion 
(NIDDK, 2007). Clearly there is an increase in the incidence of diabetes, and it calls 
for research in the prevention, cure, and treatment of patients with the disease. 
Types 1 and 2 are the two main forms of diabetes, and both can result in 
progressive β-cell failure in pancreatic islets (Cnop et al., 2005); however, the 
pathogenesis differs. Type 1 diabetes is an autoimmune disease in which there is 
selective destruction of β-cells, while type 2 diabetes has a varied progression with 
β-cell failure resulting, in some patients, from the increased demand for insulin due to 
peripheral insulin resistance (Cnop et al., 2005; Tuomi, 2005). Clinically, diabetes is 
commonly diagnosed by a fasting blood glucose concentration greater than 6.9 mM 
(American Diabetes Association, 2006). Insulin is a hormone made and released 
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from pancreatic β-cells in response to increased blood glucose levels. Insulin’s 
primary action is to increase uptake and storage of blood glucose by peripheral cells. 
When decreased β-cell activity occurs in type 1 and 2 diabetes, it leads to decreased 
insulin production, which disrupts glucose homeostasis. Although, it is important to 
note that type 2 diabetic patients can have hyperinsulinemia, which is thought to be a 
response to peripheral insulin resistance (Smith and Singleton, 2008). Therefore, the 
metabolic status of patients with diabetes always involves hyperglycemia, but can 
have either hypoinsulinemia or hyperinsulinemia. 
Neuropathy Overview 
The altered metabolic state in patients with DM leads to multiple diabetes-related 
long-term complications, such as retinopathy, nephropathy, cardiovascular disease, 
and neuropathy (American Diabetes Association, 2004). Diabetic neuropathy has 
many sub-classifications, but overall, approximately 70% of patients will diabetes will 
develop some form of nervous system damage throughout the course of their 
disease (Centers for Disease Control and Prevention, 2005). In patients with 
diabetes, neuropathy is the most common long-term complication (Vinik et al., 2000).  
In fact, diabetes is known as the leading cause of neuropathy in the United States 
and Western countries (Duby et al., 2004). Of the diabetic neuropathy subtypes, the 
most common is diabetic sensorimotor polyneuropathy (DPN) (Sinnreich et al., 
2005). Interestingly, DPN has many names: distal symmetrical sensory greater than 
motor polyneuropathy, distal peripheral neuropathy, sensorimotor neuropathy, and 
distal symmetrical polyneuropathy (Duby et al., 2004; Sinnreich et al., 2005; 
Dobretsov et al., 2007). In this body of work we were interested in studying the DPN 
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subtype of diabetic neuropathy specifically, and will simply use the nomenclature 
DPN. 
Pathophysiology 
Many theories have been explored for the pathophysiology of DPN, and most 
involve prolonged hyperglycemia as the overriding cause (Duby et al., 2004; Vinik 
and Mehrabyan, 2004; Tomlinson and Gardiner, 2008). It has been shown that 
reversing hyperglycemia by treatment with insulin can improve symptoms and/or 
delay the progression of DPN (Skyler, 2004). When insulin is present in the blood, it 
directs some glucose into cells for immediate use and the remaining glucose into 
storage in muscle, fat, and the liver (Tomlinson and Gardiner, 2008). However, in the 
setting of diabetes and hypoinsulinemia, blood glucose concentrations increase 
dramatically. Neurons are known for insulin-independent glucose uptake that is 
proportionate to extracellular concentrations of glucose. Therefore, the 
hyperglycemia translates into dangerously large increases in neuronal glucose 
(Tomlinson and Gardiner, 2008). High neuronal glucose levels result in glucose 
neurotoxicity, which is characterized by increased oxidative stress, advanced 
glycation end-product (AGE) formation, and polyol pathway flux, as depicted in 
Figure V-1 (Duby et al., 2004; Dobretsov et al., 2007; Tomlinson and Gardiner, 
2008).  
Oxidative stress is the result of glucose participation in pathological processes 
due to its higher than normal concentration (Duby et al., 2004). Increased oxidative 
stress results in increased free-radical generation, impaired antioxidant/detoxification 
pathways, and an increase in precursors for nitrosylation and lipoxidation (van Dam 
et al., 1995; Duby et al., 2004; Tomlinson and Gardiner, 2008). 
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Figure V-1. Hypothesized pathogenesis of diabetic neuropathy. Hyperglycemia 
leads to glucose neurotoxicity, which manifests as seen in this figure (adapted from 
AC Kappelle, ISNO Dutch Neuromuscular Research Support Centre, www.isno.nl). 
Glucose-induced metabolic alterations include increased polyol pathway flux, 
increased oxidative stress, and an increase in protein glycation, which all affect one-
another. These alterations can, in turn, have an effect on microvasculature, and all of 
the pathways together can impact nerve function. In addition, decreased 
neurotrophin support can also lead to nerve dysfunction.  
 19 
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 In addition, oxidative stress increases substrates for protein glycation, which occurs 
through nonenzymatic covalent bonds between glucose and proteins through the 
Maillard reaction. This, in turn, produces Schiff bases that undergo Amadori 
rearrangement to form stable AGEs (Duby et al., 2004; Tomlinson and Gardiner, 
2008). AGE formation has deleterious effects on proteins by impairing their structure 
and function (Duby et al., 2004). In addition, extra glucose in nerves can be shunted 
into the polyol pathway, which is normally limited by low glucose concentrations. 
Increased polyol pathway flux leads to the pathogenic accumulation of sorbitol and 
fructose and increased turnover of NADPH and NAD+, which are needed for 
glutathione reduction (Tomlinson, 1993; Duby et al., 2004).  
Neuronal damage in the setting of diabetes can also be due to microvascular 
complications and/or decreased neurotrophin support (Duby et al., 2004; Dobretsov 
et al., 2007). Nerves and blood vessels have physiological interdependence, and 
damage to one can affect the function of the other. Microvascular alterations have 
been documented in diabetes, such as pathologic vasoconstriction and 
hypoperfusion, and are implicated in damage to peripheral nerves (Cameron et al., 
2001). Additionally, multiple studies have reported diabetes-induced decreased 
neurotrophic support to neurons (Brewster et al., 1994; Ishii, 1995; Dyck, 1996), 
which is hypothesized to lead to nerve dysfunction and damage. Importantly, insulin 
has also been shown to act as a trophic factor for nerves (Recio-Pinto et al., 1986; 
White, 2003; Brussee et al., 2004; Toth et al., 2006), and insulin levels are 
decreased in some diabetic patients. Therefore, insulin deficiency itself may lead to 
neuropathy. 
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DPN 
As mentioned above, diabetic neuropathy has many sub-classifications as 
diabetes can affect peripheral sensory, motor, and autonomic neurons. Our focus is 
on diabetic sensorimotor polyneuropathy (DPN), which can affect both large and 
small sensory afferent nerve fibers. Large sensory nerve fibers are heavily 
myelinated and involved in proprioception, reflexes, sensorimotor function (balance 
and gait), touch, and vibration sense (Waxman, 2003). Small nerve fibers are either 
lightly myelinated or have no myelination and involved in pain, temperature sense, 
and some light touch (Waxman, 2003). Typically, DPN is characterized by a distal 
symmetrical nerve degeneration pattern, referred to as a glove-and-stocking 
distribution (Duby et al., 2004; Sinnreich et al., 2005). Some of the typical fiber 
changes found in DPN are axonal degeneration, regeneration, demyelination, and 
remyelination (Sinnreich et al., 2005). The majority of research focuses on small-fiber 
neuropathy leading to increased or decreased cutaneous pain and temperature 
sensations. Using different animal models of diabetes (mainly rat and mouse), 
allodynia, hyperalgesia, and hypoalgesia in DPN have been widely characterized 
(Calcutt et al., 1996; Drel et al., 2006; Johnson et al., 2007; Sullivan et al., 2007). 
However, there is a shortage of animal model research exploring large-fiber DPN, 
which can cause deficits in lower limb proprioception, decreased tactile sensitivity 
and vibration sense, and incoordination due to gait and balance abnormalities (Duby 
et al., 2004; Casellini and Vinik, 2007).  
Large-Fiber DPN 
The sensorimotor deficits due to large-fiber DPN, while sometimes subtle in 
nature, can lead to significant impairment. Numerous human studies have reported 
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that patients with DPN are at increased risk for falls due to decreased postural 
control, altered gait and balance, and increased body sway (Cavanagh et al., 1992; 
Uccioli et al., 1995; Richardson et al., 2001). Cavanagh et al. (1993) found that 
patients with DPN were 15 times more likely to report an injury/fall during walking 
and/or standing compared to diabetic patients without neuropathy. Falls are 
particularly dangerous as they are a main source for morbidity and mortality in the 
elderly and diabetic (Richardson, 2002; Malik, 2003; Cimbiz and Cakir, 2005).  
Sensorimotor functions include proprioception, gait, and balance, all controlled by 
the use of large sensory nerve fibers, motor nerves, and skeletal muscles. The 
muscle spindle is an important regulator of sensorimotor function, and will be 
discussed later in this chapter. Muscle weakness and atrophy are known to occur in 
patients with DPN (Cotter et al., 1989; Andersen et al., 1996; Andersen et al., 2004), 
and it has been hypothesized that problems with gait and postural control were due 
to these motor/skeletal muscle alterations (Courtemanche et al., 1996). However, 
many studies have suggested the combination of altered motor and sensory nerve 
information, perhaps in the muscle spindle, may cause the DPN patient’s dysfunction 
in gait and balance (Bergin et al., 1995; van Deursen et al., 1998; Sacco and 
Amadio, 2003; Nardone and Schieppati, 2004; Menz et al., 2004).  
Interestingly, disrupted ankle movement, in particular, has been implicated as 
leading to altered gait and balance in DPN patients (Mueller et al., 1994; Kwon et al., 
2003). During walking, the ankle performs both dorsiflexion and plantarflexion, using 
different muscle groups in order to complete the full stance and swing phases 
comprising gait. Kwon et al. (2003) reported decreased peak ankle dorsiflexion in 
patients with DPN compared to controls, which they hypothesized to be due to 
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premature activation of the soleus and medial gastrocnemius muscles that make up 
the plantar flexion phase. In order for these flexor muscles to be activated, it takes 
coordinated firing of both sensory and motor nerves and functional muscle spindles. 
Kwon et al. (2003) attributed the premature activation of flexor muscles to be a 
compensatory mechanism for patients to improve balance. However, an alternate 
hypothesis is that premature activation of soleus and medial gastrocnemius muscles 
is a result of altered muscle spindle firing of sensory and/or motor nerves.  
Nerve conduction studies have been used a great deal in the diagnosis of DPN 
clinically, and decreased nerve conduction velocity (NCV) can indicate nerve 
dysfunction even before the patient displays symptoms of DPN (Dyck et al., 2005). 
Motor and sensory NCV can be decreased experimentally in diabetic mice (Moore et 
al., 1980), and they are common measurements used as a criterion for DPN in many 
neurology clinics. However, as discussed above, DPN can affect small and large 
sensory nerve fibers, in addition to motor nerves, and NCV is used to diagnose 
general DPN. This becomes a problem clinically because NCV is a better measure of 
large sensory and motor nerve function, and does not accurately reflect the activity of 
Aδ and C fibers (Sinnreich et al., 2005; Horowitz, 2006). In contrast, for our studies of 
large-fiber DPN, nerve conduction studies add important information of the status of 
large peripheral nerves.   
Overall, the underlying neurologic mechanisms involved in large-fiber DPN 
remain poorly understood. It has been hypothesized, based on clinical studies in 
humans, that large-fiber DPN instability could be caused by altered sensorimotor 
function, specifically damaged group Ia and II sensory afferent fibers in muscle 
spindles (Simoneau et al., 1996; van Deursen et al., 1998; Nardone et al., 2007). 
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However, visualization of muscle spindles in humans is extremely difficult, and only 
through indirect testing of muscle spindle afferents, can any information be gained in 
support of the hypothesis. 
 
2. Muscle Spindle 
Anatomy 
Muscle spindles found within skeletal muscle are rapidly adapting sensorimotor 
receptors. Spindles in mice are surrounded by extrafusal muscle fibers and consist of 
a capsule containing 2 bag and 2-4 chain intrafusal fibers that run parallel with the 
extrafusal fibers. In humans, spindles can contain up to 10 intrafusal fibers (Ganong, 
2005). Nuclear bag intrafusal fibers are dilated in the center and have a dynamic 
response to extrafusal fiber stretch, while nuclear chain intrafusal fibers are thinner 
and shorter and have more of a static response to stretch. Muscle spindle sensory 
afferents are often called proprioceptors. Three subtypes of nerves innervate the 
intrafusal fibers: group Ia and II large sensory axons and gamma motor axons 
(Figure V-2A). Group Ia fibers are rapidly conducting and terminate with an 
annulospiral morphology in the equatorial (central) region of intrafusal fibers. Group II 
fibers terminate in a flower-spray morphology either side of the group Ia fibers. The 
gamma motor neurons terminate on motor end plates at the polar ends of the 
intrafusal fibers.  
During development, muscle spindle intrafusal fibers and sensory afferents 
require the trophic support of neurotrophin 3 (NT-3; Wright et al., 1997). NT-3 is 
expressed by fetal extrafusal fibers pre-natally and acts as the main ligand for 
tyrosine kinase C (trkC) receptors found on Ia and II sensory afferents (Wright et al., 
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1997). Recently it was reported that, post-natally, muscle spindle intrafusal fibers 
release NT-3 in order to maintain sensory afferent connections with the spindles 
themselves and motor neurons (Chen et al., 2002).  
Function 
Muscle spindles are involved in multiple sensorimotor behaviors such as the 
regulation of proprioception, balance, gait, and the postural response (Stapley et al., 
2002; Waxman, 2003). Figure V-2B outlines muscle spindle firing. When the muscle 
spindle intrafusal fibers are stretched, it leads to sensory nerve ending distortion, 
which allows for an increase in receptor potentials to then cause sensory nerve firing. 
Because the intrafusal fibers are in parallel with extrafusal fibers, if the extrafusal 
fibers stretch from relaxation, this causes the intrafusals to stretch and, 
concomitantly, the sensory nerves to fire. Action potentials generated from sensory 
nerves are at frequencies proportional to the amount of intrafusal and extrafusal fiber 
stretching. Because muscle spindle proprioceptors make monosynaptic connections 
with alpha motor neurons in the ventral horn of the spinal cord, spindle firing leads to 
motor neuron firing, which results in contraction of the extrafusal fibers of the same 
muscle and, through spinal cord inhibitory interneuron connections of reciprocal 
innervation, relaxation of the extrafusal fibers of the opposing or antagonistic muscle. 
In addition, gamma motor neurons receive input from descending motor pathways 
and sensitize the intrafusal fibers so that less stretch will lead to greater firing of 
spindle afferents, and vice versa. All of this results in coordinated reflexes, 
proprioception, and sensorimotor function allowing for normal gait and balance. 
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Figure V-2. Muscle spindle innervation and firing pathways. (A) Representation of a  
muscle spindle. Intrafusal fibers are shown in blue in parallel to the extrafusal fibers 
in gray. The Ia afferent fibers in green have an annulospiral morphology in the 
equatorial region of the spindle. On either side of the equatorial region are group II 
afferent fibers with a flower-spray morphology. At the ends of the intrafusal fibers are 
gamma motor neurons synapsing at neuromuscular junctions. (B) Representation of 
muscle spindle firing pathways. Spindles (in red) stretch proportionately to the 
amount and rate of stretch in extrafusal fibers (in gray) leading to sensory afferent (in 
green) firing. The sensory afferent signal travels through the cell body in the dorsal 
root ganglia through to the spinal cord where the fibers synapse with alpha motor 
neurons (in yellow) in the ventral horn. This induces alpha motor neuron firing, which 
sends the signal to extrafusal fibers of the same muscle telling it to contract. In 
addition, gamma motor neurons (in blue) bring their signal from descending motor 
pathways to the intrafusal fiber in order to sensitize it.     
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 Muscle Spindle Pathology 
Muscle spindle damage can lead to problems with proprioception, balance, 
and/or ataxic gait. Multiple studies in humans have reported changes to muscle 
spindle morphology during aging that could contribute to the increase in falls and 
ataxia seen in the elderly (Swash and Fox, 1972; Kararizou et al., 2005). Specifically, 
Swash and Fox (1972) found that aged spindles had a decreased number of 
intrafusal fibers per spindle and axonal swellings, and suggested that some spindles 
were denervated. In rodents, Egr3 null mutant mice have muscle spindle 
degeneration postnatally, which results in an ataxic gait and proprioceptive deficits 
(Chen et al., 2002). In addition, after nerve crush injury in mice, muscle spindle 
afferents degenerate with subsequent reinnervation resulting in altered sensorimotor 
function (Taylor et al., 2005).  Therefore, it is plausible that symptoms of large-fiber 
DPN, such as altered sensorimotor function, could result from damage to muscle 
spindle large afferent fibers. 
Muscle Spindle and Diabetes 
It has been hypothesized that alterations in large sensory nerve fibers innervating 
muscle spindles (group Ia and II fibers) in diabetic patients contribute to their 
manifested gait disturbances (Weis et al., 1995; Nardone et al., 2007). An indirect 
analysis of muscle spindles in the setting of diabetes was performed by Kishi et al. 
(2002). They analyzed dorsal root ganglia from STZ-treated diabetic rats and found 
that the neurons of largest size were reduced in number by 41%, which was the 
greatest decrease out of all sensory nerve populations. The largest sensory neurons 
found in the DRG correspond to the group Ia population of spindle afferents. 
Therefore, it can be inferred that after 12 months of diabetes in rats, the large spindle 
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afferents are the most highly affected population of sensory neurons. Direct analysis 
of diabetic muscle spindles was performed by Weis et al. (1995). They reported that 
STZ-induced diabetes in rats leads to spindle sensory axon dilation, sporadic axonal 
dystrophy, and axonal blebs that they described as “myelinlike cytoplasmic globules”. 
In addition, some intrafusal fibers presented with abnormal nuclei. Weis and 
colleagues (1995) also recorded decreased motor and sensory NCVs compared to 
nondiabetic rats, which is reflective of large sensory and motor nerve fiber function. 
However, it should be noted that the diabetic rats received small doses of insulin in 
order to prevent a catabolic state, which could have had an effect on the results of 
their study.  
As discussed above, NT-3 is a trophic factor involved in the development of 
muscle spindles, and it continues to be expressed by intrafusal fibers into adulthood 
in order to support sensory afferents (Copray and Brouwer, 1994).  Fernyhough et al. 
(1998) showed that NT-3 expression in skeletal muscle was decreased in the STZ-
induced diabetic rat. In addition, treatment with insulin prevented a pathologic 
decrease in NT-3. They hypothesized that large nerve fibers in muscle expressing 
trkC receptors could be receiving decreased trophic support during diabetes. 
Fernyhough and Tomlinson then went on to examine NT-3 production in the dorsal 
root and found that it was increased in the setting of diabetes (Cai et al., 1999). They 
suggest that because of decreased NT-3 production in muscle, its expression is 
increased in the dorsal root ganglia in order to maintain proprioceptors. Interestingly, 
it was also reported that NT-3 levels are significantly increased in the epidermis of 
diabetic patients compared to nondiabetics, and is concomitant with epidermal 
denervation (Kennedy et al., 1998). Taken together, these studies reveal that altered 
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NT-3 expression could be a potential mechanism for aberrant muscle spindle 
function in the setting of diabetes.   
Intrafusal bag fibers contain primarily the slow tonic myosin heavy chain (MyHC) 
isoform, while chain fibers contain primarily fast tonic MyHC (Soukup et al., 1990). 
Myosins are molecular motors involved in extrafusal and intrafusal contraction, and 
their heavy chains are characterized (slow versus fast tonic) by their oxidative 
capacity. Interestingly, Cotter et al. (1989) reported that STZ-induced diabetes in rats 
lead to a decrease in fast twitch MyHC extrafusal fibers in the extensor digitorum 
longus muscle, which was in agreement with a study from Armstrong et al. (1975) 
that found the same decrease in fast fibers in the gastrocnemius muscle with 
preservation of slow twitch fibers. To date, only MyHC diabetic alterations in 
extrafusal fibers have been reported; however, it is important to note that changes in 
extrafusal fibers could be reflected by the same pathology in intrafusal fibers due to 
both fibers containing the same MyHCs. In fact, Liu et al. (2005) examined aging 
muscle spindles and found that chain fibers were preferentially lost, which could be 
interpreted as fast twitch MyHC loss over slow twitch. Therefore, it is possible that 
diabetes induces a loss in not only extrafusal fast twitch fibers, but also intrafusal fast 
twitch fibers (the nuclear chain fibers).      
 
3. Insulin 
As briefly mentioned above, one of the main functions of insulin is glucose 
homeostasis through increasing glucose uptake from the blood and acting on insulin 
receptors (IRs) in the liver, skeletal muscle, and adipose tissue. Moreover, IRs are 
also located on perikarya of neurons, spinal nerve roots, and on peripheral axons 
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(Sugimoto et al., 2002; Toth et al., 2006). After treatment with insulin intrathecally, 
locally, and even systemically, multiple reports have shown improvements in DPN 
(Singhal et al., 1997; Huang et al., 2003; Brussee et al., 2004; Christianson et al., 
2007; Hoybergs and Meert, 2007). Specifically, Christianson et al. (2007) reversed 
diabetes-induced cutaneous mechanical insensitivity with treatment of systemic 
insulin. Additionally, in a rat model of diabetes, cutaneous allodynia was normalized 
after low-dose insulin therapy, even in the presence of sustained hyperglycemia 
(Hoybergs and Meert, 2007). Electrophysiologic deficits in diabetes can also be 
corrected by low-dose insulin treatment (Singhal et al., 1997). Therefore, it is clear 
that different paradigms of insulin treatment can result in a variety of improved 
symptoms of DPN; however, the mechanisms of action are not quite as clear.  
Importantly, insulin has actions aside from glucose homeostasis. Data reveal that 
insulin itself can act as a neurotrophic factor to support peripheral nerves by 
signaling through IRs, and even through insulin-like growth factor 1 (IGF-1) receptors 
(Recio-Pinto et al., 1986; Toth et al., 2006). Perhaps insulin is not only needed for 
glucose homeostasis in diabetic patients, but also for trophic support. It has been 
suggested that hyperglycemia may not be the only or main cause of DPN, and 
insulin may have a greater role than previously thought (Romanovsky et al., 2006; 
Dobretsov et al., 2007). In fact, Romanovsky and colleagues (2006) examined STZ-
treated rats that were normoglycemic, but insulinopenic. These animals developed 
mechanical hyperalgesia that could be attributed to low insulin levels due to their lack 
of hyperglycemia. 
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4. Exercise 
Exercise and Diabetes 
The American Diabetes Association (2007) recommends aerobic exercise for 
diabetic patients to help prevent diabetes-related complications, such as DPN. 
Exercise therapy has been evaluated recently as a treatment for DPN in humans, 
with multiple different protocols (aerobic exercise, resistance training, or exercise 
counseling) resulting in a variety of conclusions. A number of studies have reported 
improved clinical measurements of diabetic and pre-diabetic neuropathy after 
exercise therapy including intraepidermal nerve fiber (IENF) density, balance control, 
nerve conduction velocities (NCV), and vibration perception thresholds (Richardson 
et al., 2001; Balducci et al., 2006; Smith et al., 2006). Additionally, diabetic exercise 
studies have reported inconsistencies in regards to the metabolic parameters of the 
patients. Some papers report a lowering of fasting blood glucose concentrations 
(Sigal et al., 2004), while others found no changes in fasting blood glucose (Balducci 
et al., 2006; Smith et al., 2006). 
Exercise’s Mechanism of Action 
Overall, the molecular mechanisms behind treating DPN with exercise therapy 
have not been elucidated, but several hypotheses exist. Exercise can have positive 
effects directly on the cardiovascular system, on the musculoskeletal system, and 
even directly on nerves themselves. A natural physiological codependence exists 
between the peripheral nervous system and the microvascular system (Duby et al., 
2004). Therefore, it has been theorized that exercise-induced increases in blood flow 
improve nerve function. In general, it has been shown that intense exercise can 
lower blood glucose levels and hemoglobin A1C values in human diabetic patients 
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(Sigal et al., 2004). Moreover, exercise therapy increases overall skeletal muscle 
strength (Praet et al., 2008). In the nervous system, exercise therapy can act directly 
on nerves through production of neurotrophins. Molteni et al. (2004) reported that 
exercise-conditioned animals had increased nerve regeneration after peripheral 
sciatic nerve crush that was attributed to increased mRNA levels of brain-derived 
neurotrophic factor (BDNF) and NT-3 in L4-5 dorsal root ganglia of exercise mice 
compared to sedentary mice. In addition, a more recent study from the same group 
reported that exercise facilitated the recovery of locomotion following hemisection of 
the spinal cord through the regulation of BDNF (Ying et al., 2005). Recently we found 
that aerobic exercise in mice increased NT-3 in skeletal muscle (Sharma et al., 
unpublished results), which could have a positive effect on NT-3-deficient diabetic 
muscle and muscle spindles. Lastly, exercise therapy has also been reported to 
decrease oxidative stress (Villa-Caballero et al., 2007; Nojima et al., 2008), which is 
implicated as one of the main mechanisms for the development of diabetic 
neuropathy (Duby et al., 2004; Tomlinson and Gardiner, 2008).  
 
5. Study Significance 
It is increasingly apparent that DPN is a large problem for patients and the 
healthcare system in general. As mentioned above, approximately 70% of patients 
with diabetes will develop diabetic neuropathy. In addition, large-fiber neuropathy 
leading to altered gait and balance is a major cause of morbidity and mortality in 
diabetic patients. Currently, no treatments have been developed for large-fiber 
neuropathy. This is partially due to the fact that the literature discussing large-fiber 
DPN explores the disease in human patients. It is obviously important to research 
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the human condition; however, the findings are hindered by inability to directly 
examine the hypotheses generated from such work.   
Accordingly, the overall goal of this body of work was to characterize large-fiber 
diabetic sensorimotor polyneuropathy in a widely-used animal model of diabetes, 
and explore the hypothesis shared by many that the symptoms of large-fiber DPN 
could be due, in part, to aberrant muscle spindle innervation. Only a few studies, to 
our knowledge, had examined muscle spindles in the setting of diabetes, and each 
one did so in a largely descriptive fashion. With this work, we have joined together 
two fields of study – diabetic neuropathy and muscle spindles – and have tried to 
bring more insight into the human condition of large-fiber DPN. In addition, we have 
explored a relatively understudied area of DPN by looking at large-fiber neuropathy 
in animal models. It is our hope that with this and subsequent studies, the 
mechanisms of large-fiber neuropathy will be revealed and treatments will be 
identified and implemented. Overall, this work provides novel techniques for the 
assessment of muscle spindle innervation and function and uncovers inadequacies 
in our scientific knowledge that can be further addressed.   
In Chapter 2 (“Diabetic Mice Display Sensorimotor Deficits and Altered 
Muscle Spindle Ia Afferent Innervation”) we developed a novel method for 
quantifying muscle spindle Ia afferent innervation using immunohistochemistry and 
confocal microscopy that allows for visualizing very detailed morphologic alterations. 
In addition, a behavior task was identified that successfully measured sensorimotor 
deficits in diabetic mice. Importantly, muscle spindle sensory afferents were found to 
have altered morphology, lending support to many clinicians’ suspicions that deficits 
in gait and balance in DPN patients could be due to muscle spindle dysfunction.  
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In Chapter 3 (“Insulin Treatment Modifies Development of Sensorimotor 
Deficits and Repairs Muscle Spindle Ia Afferent Innervation in Diabetic Mice”) 
we used slow-release insulin pellets to treat the large-fiber neuropathy that was 
characterized in Chapter 2. Our findings lent support to the results of Chapter 2 
because insulin reversed the diabetes-induced hyperglycemia and resulted in 
concomitant behavioral and anatomical repair. However, it also raised questions 
about insulin’s mechanism of action, and will lead to future studies using insulin 
treatment directly on peripheral axons.  
In Chapter 4 (“Aerobic Exercise Therapy Improves Sensorimotor Deficits 
and Has No Effect on Variability in Muscle Spindle Ia Afferent Innervation in 
Diabetic Mice”) we were successful at creating a low-intensity aerobic exercise 
paradigm for diabetic mice and tested the effects of exercise on large-fiber DPN. 
Interestingly, exercise improved sensorimotor function, but had no effect on muscle 
spindle afferent morphology. This study will lead to future studies addressing the 
mechanism of behavioral repair, and addressing the use of other higher-intensity 
exercise protocols.   
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VI. CHAPTER TWO 
 
Diabetic Mice Display Sensorimotor Deficits and Altered Muscle 
Spindle Ia Afferent Innervation 
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1. Abstract 
Large-fiber DPN leads to balance and gait abnormalities, placing patients at 
extreme risk for falls. Large sensory axons innervating muscle spindles provide 
important feedback for balance and gait and, when damaged, can cause altered 
sensorimotor function. The current study was aimed at determining whether the 
symptoms of large-fiber DPN in type 1 and 2 diabetic mouse models are related to 
alterations in muscle spindle innervation.  
Behavioral assessments were carried out in streptozotocin (STZ)-injected 
C57BL/6 mice to quantitate diabetes-induced deficits in balance and gait. Nerve 
conduction velocities were measured to better understand the electrophysiologic 
parameters of peripheral motor and sensory nerves in diabetes. In addition, 
quantitative assessment of group Ia axon innervation of muscle spindles was carried 
out using immunohistochemistry and confocal microscopy on STZ-injected C57BL/6 
and leptin receptor-null mutant (db/db) mice.  
STZ-injected C57BL/6 mice displayed significant and progressive sensorimotor 
dysfunction associated with balance and gait. Likewise, electrophysiologic deficits 
were progressive in diabetic mice, but differed between motor and sensory nerves. 
The analysis of Ia innervation of diabetic C57BL/6 spindles revealed a range of 
abnormalities in innervation patterns suggestive of Ia axon degeneration and/or 
regeneration. The multiple distinct and abnormal Ia fiber morphologies resulted in 
substantial variability in Ia axonal width and inter-rotational distance (IRD). Likewise, 
diabetic db/db mice displayed significant variability in their IRDs compared to 
heterozygotes (db+), suggesting that damage to Ia axons occurs in both type 1 and 2 
models of DPN.  
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Similar to small sensory fibers, Ia axons are vulnerable to diabetes, and damage 
to these axons may contribute to balance and gait deficits. In addition, these studies 
provide a novel method to assist in assaying therapeutic interventions designed for 
diabetes-induced large-fiber dysfunction.  
 
2. Introduction 
As discussed in Chapter 1, DPN affects both large and small sensory afferent 
nerve fibers. There has been a shortage of animal model research exploring large-
fiber DPN, which can lead to deficits in lower limb proprioception, decreased tactile 
sensitivity and vibration sense, and incoordination due to gait and balance 
abnormalities (Duby et al., 2004; Casellini and Vinik, 2007). The sensorimotor 
deficits due to large-fiber DPN, while sometimes subtle in nature, can lead to 
significant impairment; however, the underlying neurologic mechanisms remain 
poorly understood. Nardone et al. (2007) hypothesized that large-fiber DPN 
instability could be caused specifically by damaged group Ia and II sensory afferent 
fibers in muscle spindles.  
Muscle spindle damage has been shown to lead to problems with proprioception, 
balance, and/or ataxic gait. Multiple studies in humans have reported changes to 
muscle spindle morphology during aging that could contribute to the increase in falls 
and ataxia seen in the elderly (Swash and Fox, 1972; Kararizou et al., 2005). In 
rodents, Egr3-null mutant mice have muscle spindle degeneration postnatally, 
resulting in an ataxic gait and proprioceptive deficits (Tourtellotte and Milbrandt, 
1998; Chen et al., 2002). Therefore, it is plausible that symptoms of large-fiber DPN 
could result from damage to muscle spindle large afferent fibers. Here, we examined 
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STZ-induced type 1 and leptin receptor-null mutant (db/db) type 2 diabetic mouse 
models for evidence of large-fiber DPN and muscle spindle alterations. These novel 
studies provide evidence that disrupted muscle spindle innervation in both type 1 
and 2 diabetic models may be involved, at least in part, in the sensorimotor deficits 
displayed in STZ-induced DPN.  
 
3. Experimental Procedures 
Male C57BL/6 mice were purchased at 7 weeks of age from Charles River 
(Wilmington, MA) and housed 2 mice/cage on a 12:12-hour light/dark cycle in the 
animal facility at the University of Kansas Medical Center under pathogen-free 
conditions. Male db/db mice (strain name: BKS.Cg-m+/+Leprdb/J, stock number: 
000642, background strain C57BLKS/J) were purchased from Jackson Laboratories 
(Bar Harbor, ME), and were housed at the University of Michigan under pathogen 
free conditions on a 12:12-hour light/dark cycle. A breeding colony was established, 
and the mice were genotyped 4 weeks after birth. All animals had free access to 
water and mouse chow (C57BL/6 mice: Harlan Teklad 8604, 4% kcal derived from 
fat; db/db and db+ mice: LabDiet 5001, 12% kcal derived from fat), and their use was 
in accordance with NIH guidelines and approved by the University of Kansas Medical 
Center Animal Care and Use Committee or the University of Michigan Committee on 
the Care and Use of Animals, respectively. 
STZ-injected C57BL/6 mice. Diabetes was induced in 8 week-old C57BL/6 mice 
in experimental week 0 by a single intraperitoneal injection of STZ (Sigma, St. Louis, 
MO) at 180 mg/kg body weight. The STZ was prepared in pH 4.5 10mM sodium 
citrate buffer (Wang et al., 1993), and the nondiabetic mice were injected with 400 µl 
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of the vehicle buffer. prior to the STZ or vehicle injections, mouse chow was removed 
for 4-5 hours and was not replaced until 3 hours after the injections in order to 
improve STZ uptake in pancreatic β cells. Hyperglycemia and diabetes was defined 
as a blood glucose level greater than 16mM (~288 mg/dl), and STZ-injected mice 
with blood glucose levels below the standard were not included in this study. Weight 
and tail vein blood glucose levels were measured using glucose diagnostic reagents 
(Sigma) throughout the protocol and analyzed using a two-way repeated measures 
analysis of variance (RM ANOVA) with Fisher’s protected least significant difference 
(PLSD) post hoc test.  
db/db mice. Diabetes was confirmed in the db/db mice at 8 weeks of age. In 
order to compare the muscle spindle innervation between type 1 and 2 diabetes 
models, immunohistochemical analysis and quantification of muscle spindles were 
performed on medial gastrocnemius muscles from 24 week old homozygous (db/db; 
n=3) and heterozygous (db+; n=3) leptin receptor-null mutant mice. 
Beam-walk. The beam-walk utilizes an elevated wooden balance beam to test 
sensorimotor deficits. Mice were trained during week 2 and 3 post-STZ to traverse a 
1 m long beam with a diameter of 1.2 cm in order to reach a dark, enclosed safety 
box containing food and bedding (adapted from Taylor et al., 2001; Taylor et al., 
2005). The animals were recorded for 3 trials/session while traversing a demarcated 
70 cm section of the beam on weeks 3, 5 and 10 post-STZ injection. A digital video 
camera was used to record the 3 trials. A footslip was counted if either the left or 
right hindpaw slipped off the beam. The number of footslips/mouse was averaged, 
and the data was analyzed using a two-way RM ANOVA with Fisher’s PLSD post 
hoc test.  
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Footprint analysis. Footprinting was used to analyze hindlimb gait as previously 
described in Taylor et al. (2001). Briefly, the rear paws of C57BL/6 mice were inked 
and the mice were trained to then walk along a 6 cm X 70 cm track lined with paper 
at 10 weeks post-STZ injection. Prints were scanned and analyzed using NIH 
ImageJ 1.38x software (http://rsb.info.nih.gov/ik/). For each tracking, 3-5 prints were 
analyzed for 4 parameters: step length, toe spread (distance between toes 1 through 
5), intermediate toe spread (inter-toe spread; distance between toes 2 through 4), 
and print length. Means were calculated for each animal and analyzed using an 
unpaired t-test. 
 Grid-walk. The grid-walk apparatus was used to analyze sensorimotor function 
as modified from Onyszchuk et al. (2007). Briefly, the apparatus consisted of an 
elevated 1.1 cm wire grid that was 20 cm X 35 cm. Animals were recorded with a 
digital video camera for 5 minutes while walking on the grid at 10 weeks post-STZ 
injection. Afterwards, the video was reviewed and every hindpaw step was counted, 
in addition to the number of hindpaw foot faults, or slips. Slips were counted when a 
mouse attempted to bear weight on a foot, but missed the grid and passed the foot 
through the plane of the grid. The % slips were calculated for each animal (hindpaw 
slips/total hindpaw steps x 100), and analyzed using an unpaired t-test.  
Rotorod. The rotorod (AccuRotor Rota Rod, AccuScan Instruments Inc.; 
Columbus, OH) was used to measure coordination and balance, as previously 
described in Taylor et al. (2001). Briefly, STZ-induced C57BL/6 mice were tested on 
the rotorod at a constant speed of 12 rpm for 3 trials at 9 weeks post-STZ injection. 
The latency of the mice to remain on the rotorod (in seconds) was recorded, and 
mean latencies were analyzed using an unpaired t-test. 
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Gait analysis. Using a more sophisticated approach than footprinting, gait 
analysis was performed using the DigiGait Imaging System (Mouse Specifics, Inc., 
Boston, MA). Mice were initially acclimatized in the treadmill with the motor speed set 
to zero. The speed was steadily increased to 16.7 cm/s, at which point about 4 
seconds of running was recorded through a 16 mm lens by the DigiGait Acquisition 
software. Video from each animal was then processed through the DigiGait Analysis 
software, and stance and steps were manually corrected if needed by comparing the 
plotted temporal history of paw placement with the actual video. All gait outcome 
measures produced by the analysis software were analyzed using un-paired t-tests. 
Nerve conduction velocity. Both motor and sensory nerve conduction velocities 
were recorded in the diabetic and nondiabetic mice at 6 and 10 weeks post-STZ 
injection (separate animals) using methods described in Stevens et al. 2000. 
Anesthesia was induced with an intraperitoneal injection of Avertin (1.25% v/v 
tribromoethanol, Sigma; 2.5% tert-amyl alcohol, Sigma; 200 µL/10 g body weight), 
and body temperature was monitored with a rectal probe and maintained at 37°C. In 
order to perform sciatic-tibial motor conduction, we stimulated distally at the ankle 
and proximally at the sciatic notch using supramaximal stimulation (~9.9 mA). The 
compound muscle action potential latencies were recorded from recording electrodes 
placed in the first interosseous muscle of the hind paw. The latency was calculated 
from the stimulus artifact to the onset of negative M-wave deflection. Motor nerve 
conduction velocity (MNCV) was calculated by dividing the difference between the 
proximal and distal latencies by the distance between the stimulating and recording 
electrodes. Digital sensory nerve conduction velocity (SNCV) was recorded in the 
digital nerve of the second toe with a 0.5 ms square wave pulse using the smallest 
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current to elicit a response (~2.7 mA). The recording electrode was placed behind 
the medial malleolus to record the action potential. Ten sensory nerve action 
Potentials (SNAPs) was recorded and averaged. SNCV was calculated by dividing 
the average latency by the distance between the stimulating and recording 
electrodes. Diabetic and nondiabetic nerve conduction velocities were analyzed 
using two-way ANOVAs with Fisher’s PLSD post hoc tests.  
Experimental design. Beam-walk testing was performed on 10 diabetic and 3 
nondiabetic mice on weeks 3, 5, and 10 post-STZ injection. Footprinting, grid-walk, 
and rotorod were performed on 8 diabetic and 3 nondiabetic mice at weeks 9-10 
post-STZ injection. Gait analysis was performed on 3 diabetic and 5 nondiabetic 
mice at week 6 post-STZ injection. NCV was performed at 6 weeks post-STZ on 7 
diabetic and 6 nondiabetic mice and at 10 weeks post-STZ on 6 diabetic and 6 
nondiabetic mice. Immunohistochemical analysis was performed on 10 diabetic and 
8 nondiabetic mice. Mice were sacrificed after beam-walk analysis on week 10 and 
immunohistochemical analysis and quantification of muscle spindles followed.  
Immunohistochemistry. Diabetic and nondiabetic C57BL/6 mice were deeply 
anesthetized at 10 weeks post-STZ with inhaled isoflurane (Abbott Laboratories, 
Abbott park, IL) to areflexia and decapitated prior to the removal of the right and left 
medial gastrocnemius muscles. db/db and db+ mice gastrocnemius muscles were 
dissected after an overdose of sodium pentobarbital and flash frozen in liquid 
nitrogen in 24 week old animals. Medial gastrocnemius muscles were fresh frozen on 
dry ice, sectioned with a cryostat in longitudinal serial sections at 50 µm, mounted on 
Superfrost plus slides (Fisher Scientific, Chicago, IL), and stored at -20°C. All 
immunohistochemistry was performed under humidified conditions. Following a 5 min 
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thaw, slides were incubated for 2 hours at room temperature in blocking solution 
(0.5% porcine gelatin, 1.5% normal donkey serum, and 1% Triton X-100 in 
SuperBlock Blocking Buffer [pH 7.4; Pierce, Rockford, IL]). Intrafusal bag fibers were 
visualized using a mouse anti-slow-tonic myosin heavy chain antibody (S46; 1:50; 
generous gift of Dr. Frank Stockdale, Stanford, CA). Sensory axons were visualized 
using a rabbit anti-neurofilament H antibody (NFH; 1:500; Chemicon, Temecula, CA). 
The NFH primary antibody used (#AB1991) is not affected by neurofilament 
phosphorylation. All primary antibodies were diluted in blocking solution and 
incubated with sections for 24 hours at 4°C. For fluorescence visualization, sections 
were washed 2x5 min with 0.1 M phosphate-buffered saline (PBS; pH 7.4) followed 
by incubation for 2 hours with fluorochrome-conjugated secondary antibodies 
(donkey anti-mouse Alexa 555, 1:2000; donkey anti-rabbit Alexa 488, 1:2000; 
Molecular Probes, Eugene, OR) in PBS. Prior to viewing, slides were washed 2 
times with PBS and coverslipped.  
Muscle spindle quantification. Fluorescent digital images were acquired using 
a Nikon Digital Eclipse C1si confocal microscope. Z stacks were obtained at a 1 µm 
step size (EZ-C1 Software). Approximately 3 - 6 muscle spindles per muscle were 
imaged for spindle innervation quantification. Digital Z-stack images of spindles were 
transferred to Nikon Imaging Software-Elements (NIS-Elements; Melville, NY). For 
each spindle the mean width of 3 or more axonal rotations and the mean inter-
rotational distance (the space in between the axonal rotations) between 3 or more 
rotations were calculated and recorded by a blinded observer using NIS-Elements. 
Mean axonal width and mean inter-rotational distance were analyzed using unpaired 
t-tests.   
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4. Results and Figures 
Body weight and blood glucose. One week following STZ injection, C57BL/6 
mice displayed characteristic symptoms of diabetes, including polydipsia and 
polyuria. Diabetic mice had significantly reduced weight gain and significantly higher 
blood glucose levels as early as 1 week post-STZ, which persisted through the end 
of the study until week 10 (Table VI-1). In addition, db/db mice displayed significantly 
higher body weights and blood glucose levels from week 15 through the terminal 
week 24 (Table VI-1).  
Beam-walk performance. The number of hindpaw slips counted as mice 
crossed the beam-walk apparatus was used to access sensorimotor ability. For a slip 
to be counted, the foot had to lose contact with the balance beam with the leg 
extended (Figure VI-1A). At week 3 post-STZ injection there was no significant 
difference between the mean number of slips that were counted for nondiabetic (0.9 
+/- 0.11 SEM) and diabetic (0.8 +/- 0.18 SEM; Figure VI-1B) mice. Likewise, at 5 
weeks post-STZ there was no significant difference in footslips between nondiabetic 
(0.4 +/- 0.29 SEM) and diabetic (1.1 +/- 0.19 SEM) mice; however, a trend towards a 
poorer performance in diabetic mice compared to the nondiabetic mice (Figure VI-
1B). After 10 weeks of hyperglycemia, the diabetic mice displayed a significantly 
greater number of footslips (1.3 +/- 0.27 SEM) compared to nondiabetic mice (0.2 +/- 
0.11 SEM; p < 0.05; Figure VI-1B). These results suggest that STZ-induced 
diabetes in C57BL/6 mice leads to a sensorimotor dysfunction that is detectable by 
the beam-walk apparatus.  
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Table VI-1. Body weight and blood glucose concentrations in C57BL/6 and 
leptin receptor-null mutant mice 
 Early Terminal 
 Weight Blood Glucose Weight Blood Glucose 
Nondiabetic C57BL/6 23 +/- 0.8 6.1 +/- 0.49 28 +/- 0.4 6.6 +/- 0.55 
Diabetic C57BL/6 19 +/- 0.5* 18.9 +/- 1.40** 22 +/- 1.0* 29.1 +/- 1.18** 
db+ NA NA 28 +/- 0.9 8.0 +/- 0.64 
db/db NA NA 51 +/- 1.5* 28.7 +/- 2.29* 
 
Weight and blood glucose levels measured at an early time point (1 week post-STZ 
for C57BL/6 mice or 15 weeks of age for leptin receptor null mutant mice) and the 
final time point (10 weeks post-STZ or 24 weeks of age). Weight is in grams; glucose 
concentration is in mmol/L. Data are represented as means +/- standard error of 
mean. NA represents data that were not available.  * p < 0.05 vs. nondiabetic or db+ 
mice; ** p < 0.0001 vs. nondiabetic or db+ mice. Table from Muller et al., 2008. 
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Figure VI-1. Sensorimotor evaluation on beam-walk in STZ-treated C57BL/6 diabetic 
mice. (A) Photograph of a nondiabetic C57BL/6 mouse performing the beam-walk 
task. White arrow denotes a slip of the left hindpaw. (B) Quantification of mean 
hindpaw footslips for diabetic and nondiabetic mice at 3, 5, and 10 weeks post-STZ 
injection. Diabetic mice had significantly more slips at 10 weeks post-STZ. Data are 
presented as means +/- SEM. * p < 0.05 vs. nondiabetic mice. Figure from Muller et 
al., 2008.  
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 Footprinting, grid-walk, and rotorod performance. To examine additional 
measures of sensorimotor function, footprinting, grid-walk, and rotorod tests were 
performed in STZ-induced C57BL/6 mice. Interestingly, none of the behavior tasks 
were sensitive enough to detect the sensorimotor deficits that were found during the 
beam-walk tests. All footprinting parameters were not different between nondiabetic 
and diabetic mice (Table VI-2). In addition, the grid-walk % slips and rotorod 
latencies of diabetic mice were not significantly different than nondiabetic mice 
(Table VI-2). These results suggest that the beam-walk apparatus exposes 
sensorimotor dysfunction in STZ-induced diabetes. 
Gait analysis. Many gait parameters were calculated using the DigiGait Analysis 
software. There are two main phases of gait: stance is made up of braking and 
propulsion and occurs when the paw is in contact with the surface, while swing takes 
place when the paw is not in contact with the surface. At 6 weeks post-STZ in 
C57BL/6 mice there were no significant differences between diabetic and 
nondiabetic mice for stride length, paw angle, swing, or the breaking component of 
stance (p > 0.05). Diabetic mice displayed a significantly shorter propel time (0.13 s 
+/- 0.01 SEM) for rear paws when compared to nondiabetic mice (0.15 s +/- 0.01 
SEM; p < 0.05; Figure VI-2A); however, the front paws did not show significant 
differences (p > 0.05; Figure VI-2A). In addition, diabetic mice had a greater front 
paw area (0.30 cm2 +/- 0.02 SEM) compared to nondiabetic mice (0.25 cm2 +/- 0.01 
SEM; p < 0.05; Figure VI-2B). There were no significant differences found in the rear 
paw area of diabetic and nondiabetic mice (p > 0.05; Figure VI-2B). These data 
suggest that at 6 weeks post-STZ there are minimal gait alterations in diabetic mice.     
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Table VI-2. Footprinting, grid-walk, and rotorod tests failed to detect 
sensorimotor deficits in C57BL/6 diabetic mice 
 Nondiabetic Diabetic 
Footprinting   
Step Length 8.5 +/- 0.20 7.7 +/- 0.43 
Toe Spread 0.8 +/- 0.05 0.7 +/- 0.02 
Inter-Toe Spread 0.3 +/- 0.01 0.3 +/- 0.03 
print Length 0.7 +/- 0.04 0.7 +/- 0.03 
Gridwalking 0.7 +/- 0.19 0.9 +/- 0.46 
Rotorod Latency 172 +/- 60.3 222 +/- 51.0 
 
Results from three behavioral tasks at 9-10 weeks post STZ-injection in C57BL/6 
mice. Footprinting parameters included step length, toe spread (toes 1-5), inter-toe 
spread (toes 2-4), and print length, and these analyses did not detect differences 
between nondiabetic and diabetic mice (p > 0.05). Likewise, the grid-walk did not 
detect a difference in the % slips between diabetic and nondiabetic mice (p > 0.05). 
Diabetic mice had a similar latency on the rotorod compared to nondiabetic mice (p > 
0.05). Footprinting parameters are in centimeters; gridwalking is the % slips in 5 
minutes on the grid; rotorod latency is in seconds. Data are represented as means 
+/- SEM. Table from Muller et al., 2008. 
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Figure VI-2. Gait analysis in STZ-treated C57BL/6 diabetic and nondiabetic mice. (A) 
Quantification of the amount of time diabetic and nondiabetic mice spend in the 
propel phase of their gait (seconds) at 6 weeks post-STZ injection. Diabetic mice had 
a significantly shorter propel duration in their rear paws. (B) Quantification of the 
amount of paw surface area (cm2) during locomotion in diabetic and nondiabetic 
mice at 6 weeks post-STZ injection. Diabetic mice had a significantly greater paw 
area for their front paws. Data are presented as means +/- SEM. * p < 0.05 vs. 
nondiabetic mice. 
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Nerve conduction velocity measurements. Conduction velocities of motor and 
sensory nerve fibers were accessed in nondiabetic and diabetic C57BL/6 mice 6 and 
10 weeks post-STZ injection. For MNCV, at 6 weeks post-STZ injection diabetic mice 
(41.6 m/s +/- 1.6 SEM) were not significantly different than nondiabetic mice (44.3 
m/s +/- 1.8 SEM; p > 0.05; Figure VI-3A). However, after 10 weeks of 
hyperglycemia, diabetic mice had significantly lower MNCV (49.5 m/s +/- 2.2 SEM) 
compared to nondiabetic mice (59.7 m/s +/- 2.6 SEM; p < 0.0001; Figure VI-3A). In 
comparison, digital SNCV was not different between diabetic and nondiabetic mice at 
either 6 (30.3 m/s +/- 1.2 SEM vs. 33.3 m/s +/- 1.1 SEM) or 10 weeks (32.6 m/s +/- 
1.1 SEM vs. 31.7 m/s +/- 0.9 SEM) post-STZ injection (p > 0.05 for ANOVA week 
and group differences; Figure VI-3B).  
Muscle spindles in nondiabetic mice. To quantify muscle spindle group Ia 
innervation, the muscle spindles from nondiabetic mice were visualized on a confocal 
microscope and 2 axonal parameters were measured: axonal width and inter-
rotational distance (IRD). IRD was defined as the distance between the Ia axonal 
annulospiral rotations. Within the nondiabetic group of mice, there was a mean 
axonal width of 1.3 µm with very low variability (+/- 0.19 SD) and a mean inter-
rotational distance of 3.6 µm with low variability (+/- 0.98 SD). Up to 12 muscle 
spindles can be found within 1 mouse gastrocnemius muscle, and the mean axonal 
width and IRD were very consistent not only overall in the nondiabetic group, but 
also within individual muscles (Figure VI-4A, B, C, D). These results indicate that 
within nondiabetic muscle spindles there is a high degree of homogeneity in axonal 
width and IRD.  
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Figure VI-3. Nerve conduction velocities in C57BL/6 diabetic and nondiabetic mice. 
(A) Sciatic MNCV in diabetic and nondiabetic mice at 6 and 10 weeks post-STZ 
injection. Diabetic mice have significantly decreased MNCV at 10 weeks post-STZ, 
but not at 6 weeks. (B) Digital SNCV in diabetic and nondiabetic mice at 6 and 10 
weeks post-STZ injection. Diabetic mice have no significant differences in their 
SNCV at 6 or 10 weeks. Data are presented as means +/- SEM. ** p < 0.0001 vs. 
nondiabetic mice. 
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Figure VI-4. Typical muscle spindle Ia innervation in nondiabetic C57BL/6 mice. 
Confocal optical images from the equatorial region of medial gastrocnemius muscle 
spindles from a nondiabetic mouse (A, B) illustrate consistent axonal width and inter-
rotational distance (IRD) within one muscle. In addition, spindles from 2 other 
nondiabetic mice (C, D) display similar consistency in axonal width and IRD, 
reflective of all nondiabetic animals. Red visualizes slow tonic myosin heavy chain 
(S46) expression within spindle bag fibers, and green represents NF-H positive Ia 
axons with their characteristic annulospiral morphology. Figure from Muller et al., 
2008. 
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Muscle spindles in C57BL/6 diabetic mice. Axonal width and IRD were also 
measured in muscle spindles from diabetic mice. The mean axonal width of diabetic 
mice (1.3 µm +/- 0.42 SD) was not significantly different from nondiabetic mice (p > 
0.05). In addition, the mean IRD of diabetic mice (3.9 µm +/- 1.59 SD) was not 
significantly different from nondiabetic mice (p > 0.05). However, a clear pattern 
began to appear when analyzing the values for the two spindle parameters in 
diabetic and nondiabetic mice. As described above, the nondiabetic mice had 
reliable consistency with each spindle parameter within their group and within 
individual muscles. In contrast, this consistency was not seen in the diabetic mice. 
Multiple distinct and abnormal morphologies were identified in diabetic mice that 
resulted in a high degree of variability. In diabetic mice, the mean axonal width of Ia 
axons was sometimes more narrow, sometimes wider, or sometimes average 
compared to the nondiabetic mice (Figure VI-5A, B, C; Figure VI-6A). Axonal width 
in nondiabetic mice ranged from only 0.9 µm to 1.6 µm, whereas axonal width in 
diabetic mice ranged from 0.8 µm to 2.6 µm. Similarly, Ia axons in diabetic mice 
sometimes had smaller IRDs (axon rotations closer together), sometimes larger IRDs 
(axon rotations further apart), or sometimes average IRDs compared to the 
nondiabetic mice (Figure VI-6B). IRD in nondiabetic mice ranged from only 1.3 µm to 
6.0 µm, whereas IRD in diabetic mice ranged from 1.2 µm to 8.2 µm. Although the 
size difference for small IRDs was minimal (1.2 – 1.3 µm), many diabetic animals 
displayed this small phenotype. 
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 Figure VI-5. Altered muscle spindle Ia innervation in diabetic C57BL/6 mice. 
Confocal optical images from the equatorial region of medial gastrocnemius muscle 
spindles from diabetic mice (A, B, C) show that within one diabetic muscle, both 
thinner and thicker axons are evident. These images highlight the variability in 
diabetic muscle spindle innervation morphology. Red visualizes slow tonic myosin 
heavy chain (S46) expression within spindle bag fibers, and green represents NF-H 
positive Ia axons with their characteristic annulospiral morphology. The white arrows 
denote very thin axons and the white arrowheads denote very thick axons. Figure 
from Muller et al., 2008. 
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Figure VI-6. Ia axonal width and inter-rotational distance (IRD) in diabetic and 
nondiabetic C57BL/6 mice. (A) Mean axonal width was more variable in diabetic 
mice compared to nondiabetic mice. Nondiabetic mice have a tighter range of widths 
compared to diabetic mice. The variability in diabetic mice is also higher for IRD (B) 
where nondiabetic mice have a tighter range of IRDs compared to diabetic mice. 
Note that there are increased numbers of smaller or larger Ia axons in diabetic mice 
compared to nondiabetic mice (A), and there are rotations that are spaced closer 
together or further apart in diabetic mice compared to nondiabetic mice (B). Diabetic 
mice have increased variability in axonal width in muscles of individual animals 
compared to nondiabetic mice (C). Diabetic mice also have increased variability in 
IRD in individual muscles compared to nondiabetic mice (D). CoV is the coefficient of 
variation. Black circles represent 1 muscle and black lines represent the mean CoV 
in each group (C, D). Figure from Muller et al., 2008. 
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Not only were axonal width and IRD variable between animals of the diabetic 
group (Figure VI-6A, B), but also within muscles of individual animals. The 
coefficient of variation was calculated (CoV (%) = SD/mean x 100) for each diabetic 
and nondiabetic muscle as a marker of variability. For axonal width, diabetic mice 
had a mean CoV of 30.8%, which is 7 times more variable than nondiabetic mice 
(6.5%; Figure VI-6C). For IRD, the CoV of diabetic mice also indicated more 
variability (36.1%) than nondiabetic mice (CoV = 24.5%; Figure VI-6D), but not to as 
great of an extent (1.5 times more variable). There was no correlation between 
axonal width and IRD in diabetic mice (r2 = 0.05, p = 0.737), but there is a slight 
trend towards a significant correlation in nondiabetic mice (r2 = 0.33, p = 0.057). 
Overall, these results suggest that diabetic muscle spindle Ia fibers have high 
variability in their axonal width and IRD both as a group, and within individual muscle 
spindles.  
Muscle spindles from db+ and db/db mice were analyzed to determine whether Ia 
axon variability observed in the STZ-induced type 1 mice was also present in a type 
2 diabetes model. There was no difference in axonal width between db+ and db/db 
mice (data not shown). However, similar to STZ-induced C57BL/6 diabetic mice, 
db/db mice displayed a high degree of variability in their mean IRDs compared to 
db+ mice. Ia axons in db/db mice sometimes had smaller IRDs, sometimes larger 
IRDs, or sometimes average IRDs compared to the db+ mice (Figure VI-7A, B, C). 
IRD in db+ mice ranged from 1.4 µm to 3.5 µm, where IRD in db/db mice ranged 
from 1.2 µm to 9.0 µm (Figure VI-7D). This data indicates that db/db mice display 
greater variability in their IRDs compared to db+ mice, suggesting that alterations in 
Ia axon morphology occur in both type 1 and type 2 models of DPN. 
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Figure VI-7. Variable inter-rotational distance (IRD) in db/db and db+ mice. Confocal 
optical images from the equatorial region of medial gastrocnemius muscle spindles 
from a db+ mouse showing the average IRD in the control mice (A). IRD values from 
db/db mice ranged from being smaller than db+ IRD to being much larger than db+ 
IRD (B, C). These images highlight the variability in db/db muscle spindle innervation 
morphology. Red visualizes slow tonic myosin heavy chain (S46) expression within 
spindle bag fibers, and green represents NF-H positive Ia axons with their 
characteristic annulospiral morphology. The white arrows denote small IRDs and the 
white arrowheads denote large IRDs. (D) IRD was more variable in diabetic than in 
nondiabetic mice (E) db/db mice displayed an increased variability in IRD in muscles 
of individual animals compared with diabetic mice. CoV is coefficient of variation. 
Black circles represent one muscle, and black lines represent the mean coefficient of 
variation in each group (E). Figure from Muller et al., 2008. 
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5. Discussion 
In this study, type 1 and type 2 mouse models of diabetes were used to examine 
large-fiber diabetic sensorimotor polyneuropathy. Our results reveal that STZ-
induced diabetes leads to sensorimotor behavioral deficits involving balance and gait 
detectable by the beam-walk apparatus and DigiGait Analyzer. These behavioral 
abnormalities are hypothesized to be due, in part, to the irregularities and variability 
in muscle spindle group Ia innervation. In addition, similar alterations in innervation 
were identified in a type 2 diabetes mouse model. Collectively, these results suggest 
that diabetic mice undergo damage to large sensory axons that may contribute to 
deficits in large-fiber sensory feedback associated with balance and gait.  
Behavior testing. The beam-walk apparatus has been widely used to assess 
sensorimotor function deficits following traumatic brain injury and other conditions 
resulting in altered gait, balance, and/or proprioception (Fox et al., 1998; Sherbel et 
al., 1999; Ferrer et al., 2005). Baskin et al. (2003) suggested that the beam-walk task 
is effective in detecting sensorimotor deficits resulting primarily from hindlimb 
dysfunction. In previous studies, we have used the beam-walk apparatus to evaluate 
sensorimotor function in relation to hindlimb muscle spindle innervation, and the 
performance of mice using this approach reliably mirrored the reinnervation of 
muscle spindles following nerve crush (Taylor et al., 2005). Importantly, the beam-
walk apparatus was found to be the most sensitive measure for diabetes-induced 
sensorimotor changes, as footprinting, the grid-walk, and rotorod were not able to 
detect altered behavior. The balance changes observed in the diabetic mice were 
subtle, suggesting that the beam may challenge the mice to rely on sensorimotor 
feedback more so than the other tasks discussed above. In addition, we became 
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interested in more sophisticated measures of gait analysis compared to footprinting, 
which lead us to test the mice on the DigiGait Analyzer. Unfortunately, we were only 
able to run STZ-induced C57BL/6 mice 6 weeks after diabetes induction, which 
coincides with just the beginning of sensorimotor deficits (based on beam-walk data). 
The results suggest that diabetic mice do have slight gait disturbances compared to 
nondiabetic mice, particularly during the propel phase of walking. In addition, diabetic 
mice had greater paw surface area compared to nondiabetics, indicating nerve injury 
and/or pain status. It has been reported that rats with chronic pain have decreased 
paw area (Coulthard et al., 2002), and interestingly, we know that our STZ-induced 
C57BL/6 mouse model is an insensate model of DPN. Altogether, we hypothesize 
that gait analysis at 10 weeks post-STZ would uncover greater gait disturbances, 
similar to the beam-walk data. Collectively, behavioral testing suggests that diabetic 
mice have altered sensorimotor function related to balance and gait, and that beam-
walking performance and gait analysis provide reliable indicators of these 
abnormalities in diabetic mice.  
Nerve conduction velocity. SNCV has been widely studied in rodent models of 
diabetic neuropathy, and it is thought that slowed CVs likely reflect deficits in 
conduction predominantly in large nerve fibers. However, reports of diabetes-induced 
slowed SNCV can be variable, with some studies reporting decreases (Mizisin et al., 
1999), while others report no change (Jefferys and Brismar, 1980). This may be due 
to inherent animal model differences, just as some models display cutaneous 
insensitivity while others report allodynia. Our studies revealed no reductions in 
SNCV in STZ-induced diabetic mice. It is not surprising that our model did not have 
decreased SNCV simply due to the subtle large-fiber morphologic alterations in 
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which, perhaps, some fibers compensate for others while in different states of flux. It 
is plausible to predict that rodents with significantly slowed SNCV may have a more 
severe phenotype related to spindle innervation. Ramji et al. (2007) examined motor 
nerve anatomy and electrophysiology in STZ-induced diabetic mice and found distal 
motor axon retraction and slowed MNCV. Our study did reveal slowly progressive 
decreases in MNCV in diabetic mice, which is in agreement with many other studies 
(Cameron and Cotter, 2007; Drel et al., 2007; Russell et al., 2008).  
Visual and vestibular systems. In addition to muscle spindle feedback, visual 
and vestibular systems also contribute to sensorimotor functions, and together, this 
information is integrated within central neural systems (Hirschfeld and Forssberg, 
1992). However, based on studies with pyridoxine toxicity, Stapley et al. (2002) 
reported that intact large afferent fibers from muscle spindles are necessary for the 
timing of balance/postural responses, and when damaged, the visual and vestibular 
systems cannot compensate. Thus, our results are consistent with the view that 
damage to large sensory afferent fibers innervating muscle spindles contributes 
significantly to behavioral deficits.  
Visualization of muscle spindles. Typically, muscle spindle quantification has 
involved cross section or transverse views of the muscle spindle capsule through 
light or electron microscopy (Wang et al., 1997; Wright et al., 1997; Chen et al., 
2002). This method of visualizing the spindle has been very beneficial for many 
areas of study; however, it does not allow for the intricate analysis of axon 
morphology or spacing. Visualizing muscle spindle fibers and their afferents 
longitudinally provides more information about spindle innervation, particularly 
related to axonal width and IRD. To our knowledge, our study is the first to quantify 
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Ia annulospiral endings on muscle spindle intrafusal fibers in diabetic mice, and this 
technique now provides a new assay to determine the efficacy of therapeutic 
interventions aimed at improving large-fiber diabetic neuropathy. Small-fiber 
neuropathy has benefited greatly from quantitative assessments in epidermal 
innervation, and an analogous approach has been lacking for large fibers.  
Degeneration/regeneration. Fiber changes commonly reported in DPN include 
axonal degeneration, regeneration, demyelination, and remyelination (Sinnreich et 
al., 2005). A previous study examined muscle spindles in STZ-treated diabetic rats 
and visually observed nonspecific changes in the nerve terminals of intrafusal fibers, 
such as axonal dilation and axonal dystrophy (Weis et al., 1995). Using electron 
microscopy analysis, diabetic rats revealed enlarged sciatic nerve axon terminals, 
intrafusal fiber nuclear disintegration, and increased numbers of Schwann cells, all 
suggestive of previous degeneration and subsequent regeneration (Weis et al., 
1995). This study is consistent with our more detailed observations of thicker, 
thinner, closer spaced, and further spaced axons and supports the proposed view 
that Ia axons undergo degeneration and subsequent regeneration in diabetic mice. 
Extrafusal fibers. It is plausible that extrafusal fiber atrophy could drive changes 
in spindle innervation. Although muscle wasting was not measured here, it is likely 
that muscle wasting occurs in STZ-induced diabetic mice. It may be worthwhile to 
assess spindle innervation in other muscle wasting diseases such as muscular 
dystrophy or myasthenia gravis. In human muscle spindles from patients with 
Duchenne muscular dystrophy, changes were apparent in capsule thickness, 
intrafusal fiber number and diameter (Swash and Fox, 1976). No measures of 
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quantifiable spindle innervation were documented; however, certain spindles were 
reported to be devoid of axons.  
Intrafusal fibers. Likewise, it is possible that changes in intrafusal bag fibers 
may influence Ia axon innervation. Bag fibers are typically enlarged in the equatorial 
region due to the accumulation of nuclei, and these diameter changes make it 
difficult to measure intrafusal fiber size. However, our observations suggest that 
some intrafusal fibers in diabetic mice appeared abnormal (Figure 3C), and it is 
reasonable to suggest that annulospiral innervation is influenced by intrafusal fiber 
morphology. 
Altered spindle output. Irrespective of the cause leading to altered annulospiral 
morphology, a plausible outcome of the Ia afferent fiber abnormalities reported in this 
study may be altered electrophysiological output from spindles. Muscle spindle 
afferent axons fire when the extrafusal fiber and subsequent intrafusal fiber stretch, 
leading to the distortion of Ia endings and increased activity of the Ia axon. It is 
reasonable to suggest that when Ia axon morphology is disrupted, it leads to 
changes in the firing patterns of the spindle afferent. Collectively, the varied Ia 
innervation in spindles from diabetic mice could lead to changes in overall Ia firing 
patterns and result in asynchronous Ia firing within diabetic muscles when stretched, 
as in the model shown in Figure VI-8. Furthermore, this variation in sensory input 
could affect motor neuron function as well. This hypothesis could be tested using 
electrophysiologic approaches such as H-reflex measurements and acute isolated 
spinal cord preparations focused on motor neuron output.  
Type 2 diabetes model. Our results reveal that both axonal width and inter-
rotational distance were more varied in STZ-diabetic mice compared to nondiabetic 
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mice. However, in the type 2 diabetes mouse model, axonal width was the same in 
db/db and db+ mice while inter-rotational distance varied substantially in the db/db 
but not db+ mice. The difference between db/db and STZ-induced diabetes may be 
related to the severity of neuropathy in the type 2 model or the rate of progression of 
the neuropathy. It is possible that the altered inter-rotational distance is the first sign 
of axonal damage and precedes variability in axonal width. 
Human studies. Previous studies have examined muscle spindle function in 
human neuromuscular disorders. Swash and Fox (1974) found sensory neuropathy 
led to a degeneration of Ia afferents, and they noted an attempt at regeneration of 
the sensory afferents in the form of swelling and attenuation of the Ia fibers. In 
addition, multiple studies have hypothesized that instability and postural sway in 
human diabetic neuropathy are due to poor muscle spindle function or changes in 
spindle afferents (van Deursen et al., 1998; Nardone et al., 2007). However, there 
has been little experimental research into this area due to the difficulty in accessing 
muscle spindles from human biopsies. This problematic issue reinforces the need to 
develop animal model studies to help address the pathogenesis of human large-fiber 
diabetic neuropathy.  
In conclusion, we have identified behavioral and pathological large sensory nerve 
fiber-related changes in diabetic mice. Future studies could provide new insight into 
the treatment and prevention of large-fiber complications that develop in humans 
suffering from diabetes.  
 
 
 
 72 
Figure VI-8. This figure is a working hypothesis of how altered spindle morphology 
could lead to disruptions in the spindle electrophysiologic output. If a nondiabetic 
spindle with homogeneous Ia afferent morphology is stretched, the black arrows lead 
to the hypothesized spindle electrophysiologic discharges, which are synchronous. 
However, if a diabetic spindle with heterogeneous Ia afferent morphology is 
stretched, the black arrows lead to the hypothesized discharges, which are inherently 
asynchronous due to the altered morphology. Overall, this could lead to problems 
with balance, gait, and other sensorimotor functions, as well as hyporeflexia.  
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VII. CHAPTER THREE 
 
Insulin Treatment Modifies Development of Sensorimotor Deficits 
and Repairs Muscle Spindle Ia Afferent Innervation in Diabetic 
Mice 
 75 
1. Abstract 
Muscle spindle group Ia afferent fibers are exquisitely sensitive to diabetes-
induced hyperglycemia, and their damage can lead to altered sensorimotor function. 
Insulin, or lack thereof, has multiple roles in the setting of diabetes. Not only can 
insulin increase uptake of blood glucose, but also poor insulin support to peripheral 
nerves has been implicated in the progression of DPN. The current study was aimed 
at determining whether sensorimotor and spindle deficits in a large-fiber type 1 
diabetes mouse model are reversible after treatment with insulin.  
Insulin was delivered for 4 weeks through slow-release pellets implanted 
subcutaneously in STZ-injected C57BL/6 mice. Behavioral assessments were 
carried out at baseline and after insulin treatment to quantitate deficits in balance and 
gait. Nerve conduction velocities were measured after insulin treatment to determine 
if insulin had an effect on peripheral motor and sensory nerve electrophysiology. In 
addition, quantitative assessment of group Ia axon innervation of muscle spindles 
was carried out using immunohistochemistry and confocal microscopy following 4 
weeks of insulin treatment.  
Insulin treatment significantly decreased blood glucose concentrations and 
significantly increased insulin concentrations in diabetic mice. In addition, insulin 
repaired electrophysiologic deficits in motor nerves and altered nerve conduction 
velocity in sensory nerves. Importantly, sensorimotor behavior was restored after 
insulin treatment with concomitant restoration of muscle spindle Ia afferent 
innervation patterns to levels similar to nondiabetic mice.  
Insulin therapy in STZ-induced type 1 diabetic mice completely repaired 
behavioral and neuroanatomical impairments that were associated with large-fiber 
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neuropathy. These studies provide a treatment for large-fiber neuropathy that will 
lead to further mechanistic studies in order to better understand the beneficial 
actions of insulin on nerves.  
 
2. Introduction 
As shown in Chapter 2, large-fiber diabetic neuropathy in mice results in 
sensorimotor dysfunction, progressive motor nerve conduction velocity deficits, and 
concomitant alterations in muscle spindle Ia axonal morphology. Overall, these 
changes are hypothesized to be due to diabetes-induced hyperglycemia. Therefore, 
it follows that reversing high blood glucose concentrations could improve the 
symptoms of large-fiber neuropathy.   
As described in Chapter 1, insulin is a prime candidate for decreasing 
hyperglycemia; its most widely known function is inducing glucose uptake throughout 
the body. However, insulin has also been found to have actions as a potent 
neurotrophic factor (Recio-Pinto et al., 1986; White, 2003; Brussee et al., 2004; Toth 
et al., 2006). Dobtretsov and colleagues (2007) suggest that insulin treatment in 
human patients may have actions to both correct hyperglycemia and independently 
have effects on peripheral nerves. 
Here, we have tested the hypothesis that insulin treatment in STZ-induced 
C57BL/6 type 1 diabetic mice could improve the symptoms of large-fiber neuropathy, 
such as altered sensorimotor function and disrupted neuroanatomy. This study 
provides evidence that insulin treatment reverses sensorimotor dysfunction and 
peripheral nerve alterations, irrespective of its mechanism of action.  
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3. Experimental Procedures 
Mice. Male C57BL/6 mice were purchased at 7 weeks of age from Charles River 
(Wilmington, MA) and housed 2 mice/cage on a 12:12-hour light/dark cycle in the 
animal facility at the University of Kansas Medical Center under pathogen-free 
conditions. All animals had free access to water and mouse chow (Harlan Teklad 
8604, 4% kcal derived from fat), and their use was in accordance with NIH guidelines 
and approved by the University of Kansas Medical Center Animal Care and Use 
Committee. 
Diabetes induction. Diabetes was induced as previously described in Chapter 2 
in 8 week-old C57BL/6 mice (n=11) by a single intraperitoneal injection of STZ 
(Sigma, St. Louis, MO) at 180 mg/kg body weight. The nondiabetic mice (n=6) were 
injected with 400 µl of the vehicle. Hyperglycemia and diabetes was defined as a 
blood glucose level greater than 16mM (~288 mg/dl), and STZ-injected mice with 
blood glucose levels below the standard were not included in this study. Weight and 
tail vein blood glucose levels using glucose diagnostic reagents (Sigma) were 
measured throughout the protocol and analyzed using a two-way RM ANOVA with 
Fisher’s PLSD post hoc test.  
Experimental design. In order to evaluate the effects of insulin on 
hyperglycemia-induced changes in sensory nerve fibers, mice were randomly 
assigned to 3 groups: nondiabetic (n=6), diabetic + sham pellets (n=6), or diabetic + 
insulin pellets (n=5). Baseline beam-walk behavioral testing was performed on 
weeks 1 and 5 post-STZ injection. Insulin replacement therapy began in week 6 and 
continued for a total of 4 weeks, while beam-walk performance was evaluated post-
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insulin at 10 weeks post-STZ. Mice were sacrificed after nerve conduction studies in 
week 10, and immunohistochemical analysis of muscle followed.  
Beam-walk apparatus. The beam-walk apparatus was used as described in 
Chapter 2, and briefly, the animals were recorded for 3 trials/session while traversing 
a demarcated 70 cm section of the beam on weeks 1, 5 and 10 post-STZ injection. 
The number of footslips/mouse was averaged, and the data was analyzed using a 
two-way RM ANOVA with Fisher’s PLSD post hoc test.  
Insulin Administration. Insulin pellets were administered to 5 STZ-induced 
C57BL/6 diabetic mice, while 6 diabetic and 6 nondiabetic mice received sham 
palmitic acid pellets. Insulin replacement therapy began 6 weeks post-STZ injection 
via LinBit sustained release insulin pellets (13 +/- 2 mg each; 0.1 U/24 hours/pellet; 
LinShin Canada, Inc., Scarborough, Ontario, Canada) implanted subcutaneously in 
the dorsal skin (2 pellets for the first 20g body weight and an additional pellet for 
every additional 5g body weight). All pellets remained in the mice for 4 weeks, and 
an additional insulin pellet was added if blood glucose levels failed to drop below 
16mM after one week. 
Serum insulin concentration. To determine insulin levels, serum was 
separated out from tail vein blood through centrifugation. The serum insulin 
concentration in nondiabetic, diabetic + sham, and diabetic + insulin mice was 
measured at 10 weeks post-STZ injection using an Ultrasensitive Mouse Insulin 
ELISA (Mercodia AB, Uppsala, Sweden). Briefly, equal amounts of serum samples 
(5 µL) were analyzed in duplicate, and enzyme activity was measured with a 
spectrophotometer. Insulin concentrations in unknown samples were derived by 
interpolation from a reference curve that was generated using insulin standards of 
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known concentrations in the same assay. Insulin concentration was analyzed using a 
one-way ANOVA with Fisher’s PLSD post-hoc test. 
Nerve conduction velocity. Both motor and sensory nerve conduction velocities 
were recorded at 10 weeks post-STZ injection using methods described in Chapter 
2. Diabetic and nondiabetic nerve conduction velocities were analyzed by a one-way 
ANOVA with Fisher’s PLSD post hoc test.  
Immunohistochemistry. Immediately following NCV testing, diabetic and 
nondiabetic C57BL/6 mice were decapitated prior to the removal of the right 
gastrocnemius muscles. Medial gastrocnemius muscles were processed according 
to methods in Chapter 2.  
Muscle spindle innervation. Muscle spindle large-fiber sensory innervation was 
analyzed using methods described in Chapter 2. Fluorescent digital images were 
acquired using a Nikon Digital Eclipse C1si confocal microscope. Approximately 3 - 6 
muscle spindles per muscle were imaged for spindle innervation quantification. 
Digital Z-stack images of spindles were transferred to Nikon Imaging Software-
Elements (NIS-Elements; Melville, NY). For each spindle the mean width of 3 or 
more axonal rotations and the mean inter-rotational distance in between 3 or more 
rotations were calculated and recorded by a blinded observer using NIS-Elements. 
Mean axonal width and mean inter-rotational distance were analyzed using a one-
way ANOVA with Fisher’s PLSD post hoc test. 
 
4. Results and Figures 
Body weight and blood glucose. One week following STZ injection, diabetic + 
sham (D-Sham) and diabetic + insulin (D-insulin) mice had significantly reduced 
weight gain and significantly higher blood glucose levels compared to nondiabetic 
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(ND) mice (Table VII-1). Insulin therapy began at 6 weeks post-STZ injection, and 
Figure VII-1 illustrates blood glucose levels in the weeks prior to insulin implantation 
(week 5) and just after implantation (week 7). At 5 weeks post-STZ injection D-sham 
and D-insulin mice had significantly higher blood glucose concentrations (19.6 mM 
+/- 0.4 SEM and 19.7 mM +/- 0.2 SEM, respectively) compared to ND mice (5.7 mM 
+/- 0.2 SEM; p < 0.0001; Figure VII-1). After insulin implantation, D-sham mice had 
significantly higher blood glucose concentrations (19.6 mM +/- 0.4 SEM) compared 
to ND mice (5.4 mM +/- 0.2 SEM; p < 0.0001) and, importantly, compared to D-
insulin mice (6.3 mM +/- 1.8 SEM; p < 0.0001; Figure VII-1). D-insulin mice were no 
longer statistically different than ND mice after insulin treatment (p > 0.05). In 
addition, at the end of the study (10 weeks post-STZ injection), D-Sham mice 
continued to have significantly reduced weight gain and significantly higher blood 
glucose concentrations compared to both ND mice and to N-insulin mice (Table VII-
1). These data show that insulin treatment in STZ-induced C57BL/6 diabetic mice 
reversed weight loss and hyperglycemia, bringing the metabolic status of the mice to 
levels comparable with nondiabetic mice.  
Insulin concentration. Serum insulin concentrations were measured in ND, D-
Sham, and D-insulin mice 10 weeks post-STZ injection. Diabetic mice with sham 
pellets had significantly lower blood insulin levels compared to ND mice (p < 0.05) 
and diabetic mice with insulin pellets (p < 0.05; Table VII-2). Insulin therapy 
increased insulin concentrations in diabetic mice to levels significantly higher than 
nondiabetic and D-Sham mice (p < 0.05; Table VII-2). These results suggest that the 
STZ-induced diabetes model successfully decreased circulating serum insulin levels, 
and, importantly, the insulin treatment paradigm administered was successful at  
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Table VII-1. Body weight and blood glucose concentrations 
 1 Week Post-STZ 10 Weeks Post-STZ 
 Weight Blood Glucose Weight Blood Glucose 
Nondiabetic  
 
23 +/- 0.3 6.2 +/- 0.1 29 +/- 0.8 7.0 +/- 0.3 
Diabetic + Sham  
(D-Sham) 
19 +/- 0.3* 17.8 +/- 1.0** 21 +/- 0.9 20.2 +/- 0.5 
Diabetic + Insulin 
(D-Insulin) 
21 +/- 0.7* 17.0 +/- 0.8** 26 +/- 0.7# 13.1 +/- 2.3# 
 
Weight (g) and blood glucose levels (mM) measured at 1 week post-STZ and 10 
weeks post-STZ. Data are represented as means +/- standard error of mean. * p < 
0.05 vs. nondiabetic; ** p < 0.0001 vs. nondiabetic; # p < 0.05 vs. diabetic + sham. 
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Figure VII-1. Blood glucose concentrations pre-insulin and during insulin treatment. 
Quantification of mean blood glucose concentrations weeks 5 (pre-insulin) and 7 
(during insulin treatment) post-STZ. At 5 weeks post-STZ both diabetic + sham and 
diabetic + insulin mice had significantly higher blood glucose levels compared to 
nondiabetic mice. After insulin treatment began, diabetic + sham mice had 
significantly higher blood glucose levels compared to both nondiabetic and diabetic + 
insulin treated mice. Data presented as means +/- SEM. * p < 0.0001 vs. 
nondiabetic; # p < 0.0001 vs. diabetic + insulin. 
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Table VII-2. Serum Insulin Concentrations 
 Mean Insulin 
Concentration (µg/L) 
SEM 
Nondiabetic 2.1 0.7 
Diabetic + Sham  0.6* 0.1 
Diabetic + Insulin 12.2# 3.8 
 
Serum insulin levels measured at 10 weeks post-STZ, after 4 weeks of insulin 
treatment. Diabetic + sham mice have significantly lower insulin levels compared to 
nondiabetic and diabetic + insulin mice. Additionally, diabetic + insulin mice have 
significantly higher insulin levels compared to nondiabetic and diabetic + sham mice. 
* p < 0.05 vs. nondiabetic and diabetic + insulin. # p < 0.05 vs. nondiabetic and 
diabetic + sham. 
 85 
increasing serum insulin concentrations in treated mice. 
Beam-walk performance. Insulin replacement therapy was administered to 
determine if the behavioral and anatomical changes in STZ-induced diabetic mice 
were reversible. At 1 and 5 weeks post-STZ injection, no significant differences in 
beam-walk slips were apparent between ND, D-Sham, and D-Insulin mice (p > 0.05; 
Figure VII-2). However, after 10 weeks post-STZ, the D-Sham mice displayed 
significantly more slips (1.2 +/- 0.07 SEM) compared to ND mice (0.5 +/- 0.20 SEM, 
p = 0.05). Importantly, diabetic mice treated with insulin improved their beam 
performance, and had significantly fewer slips (0.3 +/- 0.07 SEM) compared to D-
Sham mice (p < 0.05) and were not significantly different than ND mice (p > 0.05; 
Figure VII-2). These data indicate that insulin replacement therapy in diabetic mice 
can reverse the progression of sensorimotor deficits.  
Peripheral nerve electrophysiology. Sciatic motor nerve conduction velocity 
(MNCV) was significantly decreased at 10 weeks post-STZ injection in D-sham mice 
compared to ND and D-Insulin mice (p < 0.05; Figure VII-3A). Insulin therapy was 
able to increase MNCV to levels comparable with nondiabetic mice. Similar to 
Chapter 2, there was no difference in the nerve conduction velocity of the digital 
nerve (SNCV) between diabetic + sham and nondiabetic mice (p > 0.05 D-Sham vs. 
ND; Figure VII-3B). Interestingly, insulin treatment in diabetic mice resulted in a 
significantly lower SNCV compared to nondiabetic and diabetic + sham mice (p < 
0.05; Figure VII-3B). These results suggest that insulin treatment in diabetic mice 
repairs MNCV to levels comparable with nondiabetic mice and altered SNCV. 
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Figure VII-2. Sensorimotor evaluation on beam-walk in nondiabetic, diabetic + sham, 
and diabetic + insulin mice. Quantification of mean hindpaw footslips at weeks 1, 5, 
and 10 post-STZ injection. Diabetic + sham mice had significantly more slips at 10 
weeks post-STZ compared to nondiabetic and diabetic + insulin mice. Arrow denotes 
time of insulin pellet administration at 6 weeks post-STZ. Data are presented as 
means +/- SEM. * p < 0.05 diabetic + sham vs. nondiabetic and diabetic + insulin. 
Figure from Muller et al., 2008. 
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Figure VII-3. Nerve conduction velocity in nondiabetic, diabetic + sham, and diabetic 
+ insulin mice. (A) Quantification of mean sciatic motor nerve conduction velocity at 
10 weeks post-STZ injection. Diabetic + sham mice had significantly lower 
conduction velocity compared to nondiabetic and diabetic + insulin mice. (B) 
Quantification of mean digital sensory nerve conduction velocity at 10 weeks post-
STZ injection. Diabetic + insulin mice had significantly lower conduction velocity 
compared to nondiabetic and diabetic + sham mice. Data presented as means +/- 
SEM. * p < 0.05 vs. nondiabetic and diabetic + insulin. # p < 0.05 vs. nondiabetic and 
diabetic + sham.  
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Muscle spindles after treatment with insulin. In order to evaluate insulin’s 
effect on muscle spindle innervation, axonal width and inter-rotational distance were 
also measured in muscle spindles from D-Sham vs. D-Insulin mice. The multiple 
axonal morphologies previously identified in diabetic mice in Chapter 2 that resulted 
in a high degree of variability were reversed in insulin-treated diabetic mice. In D-
Insulin mice, the mean axonal width of Ia axons was more consistent than in D-Sham 
mice, and was comparable to nondiabetic mice from Chapter 2 (Figure VII-4A). 
Axonal width in D-Insulin mice ranged from only 0.9 µm to 2.0 µm, whereas axonal 
width in D-Sham mice ranged from 0.8 µm to 2.9 µm. Similarly, IRD variability was 
decreased in D-Insulin mice (Figure VII-4B). IRD in D-Insulin mice ranged from only 
1.6 µm to 4.0 µm, whereas IRD in D-Sham mice ranged from 1.2 µm to 8.0 µm.  
Not only was axonal width and IRD variability decreased in insulin treated mice, but 
also within muscles of individual animals. For axonal width, D-Sham mice had a 
mean CoV of 44.4%, which is 2.5 times more variable than D-Insulin mice (18.0%; 
Figure VII-4C). For IRD, the CoV of D-Sham mice also indicated about 2 times more 
variability (37.4%) than D-Insulin mice (CoV = 17.6%; Figure VII-5D). These results 
suggest that insulin therapy repairs spindle Ia afferent axonal innervation variability.  
 
5. Discussion 
Results from this study reveal that sustained release insulin delivery systemically 
for 4 weeks in STZ-induced C57BL/6 diabetic mice decreased blood glucose levels, 
increased body weights, and increased serum insulin concentrations to levels higher 
than nondiabetic mice. In addition, insulin had positive effects on peripheral nerves 
through increasing motor nerve conduction velocities, altering sensory nerve 
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Figure VII-4. Insulin treatment repairs altered muscle spindle innervation in diabetic 
mice. (A) Mean axonal width was less variable with a tighter range in diabetic + 
insulin mice compared to diabetic + sham mice. The variability in diabetic + insulin 
mice was also lower for IRD (B). Diabetic + insulin mice also decreased their internal 
variability in axonal width and IRD in muscles of individual animals compared to 
diabetic + sham mice (C and D). CoV is the coefficient of variation. Black circles 
represent one muscle, and black lines represent the mean CoV in each group (C and 
D). Figure from Muller et al., 2008. 
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conduction velocities, and decreasing the diabetes-driven pathologic muscle spindle 
Ia innervation variability. All of these changes resulted in improved sensorimotor 
function as measured by beam-walk analysis. Collectively, insulin treatment of STZ-
induced diabetic mice effectively reversed behavioral and anatomical large-fiber 
neuropathy deficits. 
Insulin and glucose homeostasis and/or neurotrophism. As expected, insulin 
treatment in diabetic mice resulted in decreased blood glucose levels and reversed 
weight loss. However, these data are integral to the major pitfall of this study: the 
inability to tease out the mechanism by which insulin exerted positive effects. It is 
known that insulin can act as a neurotrophic factor through signaling on insulin 
receptors (Recio-Pinto et al., 1986; White, 2003; Brussee et al., 2004; Toth et al., 
2006). Insulin receptors (IRs) are located on perikarya, nerve roots, and peripheral 
axons (Sugimotor et al., 2002; Toth et al., 2006). Therefore, in our study insulin could 
be directly supporting proprioceptive axons or their cell bodies in the DRG, insulin 
could simply be decreasing blood glucose and concomitant nerve glucose 
concentrations to reverse glucose toxicity, or it could be acting through both 
mechanisms simultaneously to result in repaired sensorimotor function, nerve 
conduction velocity, and muscle spindle innervation morphology. Most likely the latter 
occurred in this study – a combination of metabolic and neurotrophic mechanisms. 
Multiple reports have shown improvements in DPN after treatment with insulin 
intrathecally, locally, and systemically (Singhal et al., 1997; Huang et al., 2003; 
Brussee et al., 2004; Hoybergs and Meert, 2007). Our results are in agreement with 
these studies; however, one major difference is that these studies reported no 
changes in blood glucose concentrations. Therefore, they were able to infer that the 
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improvements in DPN were due to direct trophic effects of insulin on peripheral 
nerves. Further studies supplying insulin intrathecally or in low doses directly in the 
nerves (such as in Singhal et al., 1997) would help narrow down insulin’s mechanism 
of action in repairing large-fiber neuropathy in STZ-induced diabetic mice. 
 Toth et al. (2006) reported that intrathecal insulin delivery decreased axonal 
atrophy and lead to increased regeneration after nerve crush injury in rats. In 
contrast, near-nerve insulin delivery did not have an effect on axonal atrophy or 
regeneration (Toth et al., 2006). Based on these data, systemic insulin delivery 
leading to decreased blood glucose levels (such as in our model) might not be 
expected to have a direct effect on regeneration of peripheral nerves. However, we 
hypothesize that our diabetes model had inherent differences, when compared to the 
nerve injury model, which could lead to increased nerve support and/or regeneration 
even with only an increase in systemic insulin. First of all, our type 1 diabetes mouse 
model had significantly decreased insulin production, which resulted in lowered 
insulin trophic support to peripheral nerves. Perhaps because the diabetic nerves 
were “starved” for insulin, unlike the injury model with normal circulating insulin 
levels, any contact with insulin to the axon and/or perikarya, could have a positive 
neurotrophic effect. Secondly, the circulating blood insulin levels in our diabetic + 
insulin mice were significantly greater than nondiabetic mice with normoinsulinemia. 
Normally, insulin circulating in the blood will enter the cerebrospinal fluid and have 
direct contact with the dorsal root ganglia and anterior horn cells. It is possible that 
with higher than normal levels of circulating insulin, there was a greater amount of 
insulin acting on IRs supporting the cell bodies of both peripheral sensory and motor 
neurons.  
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Insulin and large sensory fibers. Studies have examined the effects of insulin 
therapy on diabetes-induced peripheral small-fiber neuropathy. In a model of 
insensate neuropathy, STZ-induced diabetic mice that were treated with sustained 
release insulin pellets had reversed mechanical insensitivity (Christianson et al., 
2007). In addition, in the STZ-induced diabetic rat model of painful neuropathy, low-
dose sustained release insulin therapy resulted in normalization of mechanical 
allodynia, without changes in blood glucose levels (Hoybergs and Meert, 2007). 
Lastly, insulinopenic STZ-treated rats without hyperglycemia displayed mechanical 
hyperalgesia that was also reversible with low-dose insulin replacement 
(Romanovsky et al., 2006). No studies, to our knowledge, have examined large-fiber 
neuropathy behavioral deficits after insulin therapy. Interestingly, in the current study 
we have reversed balance sensorimotor dysfunction through treatment with insulin. 
Therefore, not only does insulin have positive actions on dysfunctional small sensory 
fibers, but it can also repair large sensory fiber deficits.  
Insulin and nerve conduction velocity. Nerve conduction velocity 
improvements have been reported after insulin therapy in many studies (Singhal et 
al., 1997; Huang et al., 2003; Brussee et al., 2004). Here, we have also reported that 
insulin replacement increased sciatic MNCV to levels comparable with nondiabetic 
mice. Of interest are the changes in SNCV. Reports in diabetic rats and mice have 
shown decreases in SNCV at different time points (Mizisin et al., 1999; Huang et al., 
2003; Brussee et al., 2004). In contrast, Jefferys and Brismar (1980) reported no 
changes in SNCV due to diabetes. In Chapter 2, we reported no changes in digital 
SNCV in our animal model of large-fiber diabetic neuropathy, and those results are 
consistent with the current study. However, unexpectedly, here we have reported 
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that insulin treatment in the diabetic mice significantly lowered their SNCV. Nerve 
conduction velocity can be affected by sodium channel expression and function 
(Yokota et al., 1994; Kearney et al., 2002). Moreover, Craner et al. (2002) examined 
the expression and protein levels of multiple sodium channels in the setting of STZ-
induced diabetes in rats, and found alterations in NaV1.3, NaV1.6, and NaV1.8 levels 
in both large and small DRG neurons. Administration of growth factors in diabetic 
and axotomized animals has resulted in the reversal of sodium channel alterations 
(Fernyhough et al., 1993; Black et al., 1997). Therefore, it is possible that insulin 
treatment in the current study could have altered sodium channel expression in 
peripheral sensory nerves. If, in fact, the sensory nerves are going through 
regeneration after insulin therapy, it could be hypothesized that SNCV was reduced 
due to sodium channel flux. Perhaps, if the SNCV was measured 1 or 2 weeks later, 
we would expect to see increases in conduction velocity.   
In conclusion, we have reported that 4 weeks of sustained-release insulin 
treatment in STZ-induced C57BL/6 diabetic mice is successful at reversing large-
fiber sensorimotor deficits and restoring muscle spindle Ia afferent innervation 
variability. Future studies could address the molecular mechanisms by which insulin 
had positive actions on peripheral sensory and motor nerves. Additionally, studies 
could test the use of insulin therapy independent of glucose alterations in the large-
fiber DPN model. Even though insulin is a common treatment for type 1 and 
sometimes type 2 diabetes in humans, it is only given to lower blood glucose levels. 
It is possible that it could be administered locally to nerves in low doses in order to 
trophically support the peripheral nerves and prevent and/or reverse the symptoms 
of DPN.  
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VIII. CHAPTER FOUR 
 
Aerobic Exercise Therapy Improves Sensorimotor Deficits and 
Has No Effect on Variability in Muscle Spindle Ia Afferent 
Innervation in Diabetic Mice 
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1. Abstract 
Alterations in group Ia sensory afferent fibers innervating muscle spindles lead to 
sensorimotor and gait disturbances in STZ-induced type 1 diabetic mice. 
Sensorimotor and nerve dysfunction can be reversed through insulin treatment. 
Exercise has been suggested as a therapy for DPN, and we aimed to determine 
whether symptoms of large-fiber DPN and muscle spindle morphologic variations 
could be repaired by aerobic exercise therapy.   
STZ-induced diabetic and nondiabetic mice performed low-intensity exercise 
therapy consisting of brisk walking on a treadmill for 4 weeks. Sensorimotor 
behavioral assessments were made before and after exercise therapy. 
Electrophysiologic studies and muscle spindle quantification were carried out at the 
end of the exercise study.  
Low-intensity exercise therapy did not have an effect on blood glucose 
concentrations, body weight, or blood insulin concentrations in diabetic or 
nondiabetic mice. In addition, exercise had no effect on nerve conduction velocities 
in peripheral motor or sensory nerves. Interestingly, exercise therapy did improve 
sensorimotor dysfunction in diabetic mice. Lastly, exercise therapy had no effect on 
the muscle spindle Ia afferent innervation patterns in diabetic or nondiabetic mice.  
Low-intensity exercise therapy can improve sensorimotor deficits in STZ-induced 
diabetic mice; however, it does not have an effect on the electrophysiologic 
properties or anatomical structure of peripheral sensory nerves. These studies 
provide a treatment for large-fiber DPN in type 1 diabetic mice, and will allow for 
future studies on the mechanisms behind sensorimotor improvement after exercise.  
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2. Introduction 
As discussed in Chapter 1, aerobic exercise therapy is recommended for diabetic 
patients to help prevent diabetes-related complications, such as DPN. A number of 
studies have reported improved clinical measurements of diabetic and pre-diabetic 
neuropathy after exercise therapy including intraepidermal nerve fiber (IENF) 
density, balance control, nerve conduction velocities (NCV), and vibration perception 
thresholds (Richardson et al., 2001; Balducci et al., 2006; Smith et al., 2006). 
Overall, the molecular mechanisms behind treating DPN with exercise therapy have 
not been elucidated, but several hypotheses exist. Exercise can have positive effects 
directly on the cardiovascular system, on the musculoskeletal system, and even 
directly on nerves themselves.  
Here we tested the hypothesis that exercise therapy could improve sensorimotor 
deficits in mice with large-fiber neuropathy, perhaps through repair of Ia axonal 
morphology. We examined the effects of aerobic low-intensity exercise on STZ-
induced type 1 diabetic mice for evidence of large-fiber DPN improvement. These 
experiments provide evidence that exercise has positive effects on sensorimotor 
function without altering muscle spindle innervation or metabolic status in STZ-
induced diabetic mice.  
 
3. Experimental procedures 
Mice. Male C57BL/6 mice were purchased at 7 weeks of age from Charles River 
(Wilmington, MA) and housed 2 mice/cage on a 12:12-hour light/dark cycle in the 
animal facility at the University of Kansas Medical Center under pathogen-free 
conditions. All animals had free access to water and mouse chow (Harlan Teklad 
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8604, 4% kcal derived from fat), and their use was in accordance with NIH guidelines 
and approved by the University of Kansas Medical Center Animal Care and Use 
Committee. 
Diabetes induction. Diabetes was induced as previously described in Chapter 2 
in 8 week-old C57BL/6 mice (n=21) by a single intraperitoneal injection of STZ 
(Sigma, St. Louis, MO) at 180 mg/kg body weight. The nondiabetic mice (n=16) were 
injected with 400 µl of the vehicle. Hyperglycemia and diabetes was defined as a 
blood glucose level greater than 16mM (~288 mg/dl), and STZ-injected mice with 
blood glucose levels below the standard were not included in this study. Weight and 
tail vein blood glucose levels using glucose diagnostic reagents (Sigma) were 
measured throughout the protocol and analyzed using a two-way RM ANOVA with 
Fisher’s PLSD post hoc test. Blood insulin concentration was measured in 5 µL of 
serum at 10 weeks post-STZ injection as described in Chapter 3. Insulin 
concentration was analyzed using a one-way ANOVA with Fisher’s PLSD post-hoc 
test.  
Experimental design. In order to evaluate the effects of aerobic exercise on 
hyperglycemia-induced changes in sensory nerve fibers, mice were randomly 
assigned to 4 groups: nondiabetic sedentary (n=8), nondiabetic exercise (n=8), 
diabetic sedentary (n=10), or diabetic exercise (n=11). Baseline beam-walk 
behavioral testing was performed on weeks 1 and 5 post-STZ injection. Aerobic 
exercise therapy began in week 6 and continued for a total of 4 weeks, while beam-
walk performance was evaluated post-exercise at 10 weeks post-STZ. Mice were 
sacrificed after nerve conduction studies in week 10, and immunohistochemical 
analysis of muscle followed.  
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Beam-walk apparatus. The beam-walk apparatus utilizes an elevated wooden 
balance beam to test for sensorimotor deficits, and has been found to reveal muscle 
spindle dysfunction in both a nerve injury model and a diabetic mouse model (Taylor 
et al., 2003; Muller et al., 2008). It was used as described in Chapter 2, and briefly, 
the animals were recorded for 3 trials/session while traversing a demarcated 70 cm 
section of the beam on weeks 1, 5 and 10 post-STZ injection. The number of 
footslips/mouse was averaged, and the data was analyzed using a two-way RM 
ANOVA with Fisher’s PLSD post hoc test.  
Aerobic exercise therapy. Exercise training was carried out on the nondiabetic 
and diabetic exercise groups 5 weeks post-STZ injection using two 6-lane motorized 
treadmill (Columbus Instruments, Columbus, OH). Training consisted of 3 days of 
acclimatization to the treadmill itself, and then subsequent increasing speeds of the 
treadmill. The exercise protocol began 6 weeks post-STZ injection for 30 
minutes/day, 5 days/week for a total of 4 weeks. The mice briskly walked on a level 
surface at a speed of 10 m/min.  
Nerve conduction velocity. Both motor and sensory nerve conduction velocities 
were recorded at 10 weeks post-STZ injection using methods described in Chapter 
2. Diabetic and nondiabetic nerve conduction velocities were analyzed by a one-way 
ANOVA with Fisher’s PLSD post hoc test.  
Immunohistochemistry. Immediately following NCV testing, diabetic and 
nondiabetic C57BL/6 mice were decapitated prior to the removal of the right 
gastrocnemius muscles. Medial gastrocnemius muscles were processed according 
to methods in Chapter 2.  
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Muscle spindle innervation. Muscle spindle large-fiber sensory innervation was 
analyzed using methods described in Chapter 2. Fluorescent digital images were 
acquired using a Nikon Digital Eclipse C1si confocal microscope. Approximately 3 - 6 
muscle spindles per muscle were imaged for spindle innervation quantification. 
Digital Z-stack images of spindles were transferred to Nikon Imaging Software-
Elements (NIS-Elements; Melville, NY). For each spindle the mean width of 3 or 
more axonal rotations and the mean inter-rotational distance (the space in between 
the axonal rotations) in between 3 or more rotations were calculated and recorded by 
a blinded observer using NIS-Elements. Mean axonal width and mean inter-rotational 
distance were analyzed using a one-way ANOVA with Fisher’s PLSD post hoc test. 
 
4. Results and Figures 
Blood glucose concentrations and body weight. STZ-induced diabetes lead 
to hyperglycemia (> 16 mM) 1 week post-STZ injection and throughout the study that 
was significantly higher than nondiabetic glucose concentrations (p < 0.0001 diabetic 
sedentary (D-S) vs. nondiabetic sedentary (ND-S) mice; Figure VIII-1A). Nondiabetic 
mice that were exercised (ND-E) continued to display normoglycemia, while diabetic 
exercise (D-E) mice continued to display hyperglycemia (Figure VIII-1A). Therefore, 
exercise therapy had no effect on blood glucose concentrations (p > 0.05 ND-S vs. 
ND-E mice and D-S vs. D-E mice). Likewise, the body weight of diabetic mice was 
significantly lower than that of nondiabetic mice starting 1 week post-STZ (p < 0.05) 
and continuing throughout the course of the study (Figure VIII-1B).  However, 
exercise did not alter body weight in nondiabetic or diabetic mice (p > 0.05 ND-S vs. 
ND-E mice and D-S vs. D-E mice; Figure VIII-1B).  
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Figure VIII-1. Blood glucose concentrations and body weights in diabetic and 
nondiabetic sedentary and exercise mice. (A) Quantification of mean blood glucose 
concentrations weeks 1 and 5 post-STZ (pre-exercise) and weeks 6-10 post-STZ 
(throughout exercise). Diabetic sedentary and exercise mice had significantly higher 
glucose levels compared to nondiabetic sedentary and exercise mice throughout the 
course of the study. (B) Quantification of mean body weights weeks 1 and 5 post-
STZ (pre-exercise) and weeks 6-10 post-STZ (throughout exercise). Diabetic 
sedentary and exercise mice had significantly lower body weights compared to 
nondiabetic sedentary and exercise mice throughout the course of the study. Data 
presented as means +/- SEM. * p < 0.05 vs. nondiabetic sedentary and exercise 
mice. 
 104 
 
 105 
Blood insulin concentrations. Blood insulin concentrations were measured in 
ND-S, ND-E, D-S, and D-E mice 10 weeks post-STZ injection. STZ-induced D-S 
mice had significantly lower blood insulin levels compared to ND-S mice (p < 0.05; 
Figure VIII-2). However, exercise therapy had no effect on insulin concentrations (p 
> 0.05 ND-S vs. ND-E mice and D-S vs. D-E mice; Figure VIII-2). These results 
suggest that the metabolic parameters measured here (blood glucose concentration, 
weight, and insulin concentration) were all altered by diabetes, but were not changed 
after 4 weeks of exercise therapy.  
Beam-walk performance. In Chapter 2, STZ-induced diabetes leads to 
sensorimotor dysfunction by 10 weeks post-STZ injection as measured by hindpaw 
footslips on the beam-walk apparatus. Here, D-S mice displayed a significantly 
greater number of hindpaw footslips 10 weeks post-STZ injection compared to ND-S 
mice (p < 0.05) and ND-E mice (p < 0.05; Figure VIII-3). Importantly, 4 weeks of 
exercise therapy in diabetic mice significantly decreased hindpaw footslips compared 
to sedentary diabetic mice (p < 0.05; Figure VIII-3). The number of hindpaw footslips 
in D-E mice was not statistically different from ND-S (p > 0.05) or ND-E (p > 0.05) 
mice. These results suggest that 4 weeks of exercise therapy in diabetic mice 
improved sensorimotor function as tested on the balance beam to levels comparable 
to nondiabetic mice. However, exercise had no effect on the sensorimotor 
performance of nondiabetic mice. 
Peripheral nerve electrophysiology. Sciatic motor nerve conduction velocity 
(MNCV) was significantly decreased at 10 weeks post-STZ injection in D-S 
compared to ND-S mice (p < 0.0001; Figure VIII-4A). However, exercise training did  
 
 106 
Figure VIII-2. Blood insulin concentrations in diabetic and nondiabetic sedentary and 
exercise mice. Quantification of mean blood insulin concentrations at 10 weeks post-
STZ injection. Diabetic sedentary and exercise mice had significantly lower insulin 
levels compared to nondiabetic sedentary and exercise mice. Data presented as 
means +/- SEM. * p < 0.05 vs. nondiabetic sedentary and exercise mice. 
 107 
 
 108 
Figure VIII-3. Sensorimotor evaluation on beam-walk in diabetic and nondiabetic 
sedentary and exercise mice. Quantification of mean hindpaw footslips at weeks 1 
and 5 post-STZ (pre-exercise) and 10 weeks post-STZ (terminal exercise week). 
Diabetic sedentary mice had significantly more slips at 10 weeks post-STZ compared 
to nondiabetic sedentary, nondiabetic exercise, and diabetic exercise mice. Data are 
presented as means +/- SEM. * p < 0.05 vs. nondiabetic sedentary and exercise and 
diabetic exercise mice. 
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Figure VIII-4. Nerve conduction velocity in diabetic and nondiabetic sedentary and 
exercise mice. (A) Quantification of mean sciatic motor nerve conduction velocity at 
10 weeks post-STZ injection. Diabetic sedentary and exercise mice had significantly 
lower conduction velocity compared to nondiabetic sedentary and exercise mice. (B) 
Quantification of mean digital sensory nerve conduction velocity at 10 weeks post-
STZ injection. Data presented as means +/- SEM. * p < 0.05 vs. nondiabetic 
sedentary and exercise mice. 
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not affect MNCV in either nondiabetic (p > 0.05 ND-S vs. ND-E) or diabetic mice (p > 
0.05 D-S vs. D-E; Figure VIII-4A). Similar to previous reports (Muller et al., 2008), 
there was no difference in the nerve conduction velocity of the digital nerve (SNCV) 
between diabetic and nondiabetic mice (p > 0.05 D-S vs. ND-S; Figure VIII-4B). 
Likewise, exercise had no effect on either nondiabetic (p > 0.05 ND-S vs. ND-E) or 
diabetic mice (p > 0.05 in D-S vs. D-E; Figure VIII-4B). These results suggest that 
diabetes alters MNCV, but not SNCV. In addition, this exercise therapy paradigm did 
not alter any of the electrophysiologic parameters measured here. 
Diabetic sedentary muscle spindle Ia afferent morphology. As described 
previously in Chapters 2 and 3, diabetic muscle spindles display increased 
morphologic variability in mean axonal width and mean IRD compared to nondiabetic 
spindles. This finding was confirmed here; muscle spindle variability was greater in 
diabetic mice compared to nondiabetic mice. Figure VIII-5 illustrates the differences 
in D-S muscle spindles compared to ND-S spindles. An example of a ND-S muscle 
spindle is shown in Figure VIII-5A. Diabetic Ia axons from sedentary mice can have 
a similar axonal width to ND-S mice (Figure VIII-5B), but interestingly they can also 
display much wider (Figure VIII-5C) or much thinner (Figure VIII-5D) axonal widths 
both in between diabetic animals and within the same muscle. However, this did not 
result in a difference in mean axonal width. The mean axonal width in D-S mice was 
1.51 µm, which was not significantly different from ND-S mice (1.43 µm; p > 0.05; 
Table VIII-1). However, the range of mean axonal width in D-S mice was 2.56 µm, 
much greater than the range of 0.91 µm in ND-S mice (Table VIII-1). By plotting the 
number of muscle spindles with particular axonal widths in a histogram (Figure VIII-
5E), it is apparent that the ND-S mice had a very tight range of axonal widths, 
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Figure VIII-5. Altered muscle spindle innervation in diabetic sedentary mice. (A) 
Confocal optical image from the equatorial region of the medial gastrocnemius 
muscle spindle from a nondiabetic sedentary mouse shows the typical axonal width 
and inter-rotational distance displayed by nondiabetic mice. (B, C, D) Confocal 
optical images from a diabetic sedentary mouse show that muscle spindles in 
diabetic mice can have axonal widths that are comparable with nondiabetics (B), that 
are much wider than nondiabetics (C), or even much thinner than nondiabetics (D). 
(B, C, D) These images highlight the variability in diabetic muscle spindle innervation 
morphology. Red visualizes slow tonic myosin heavy chain (S46) expression within 
spindle bag fibers, and green represents NF-H positive Ia axons with their 
characteristic annulospiral morphology. The white arrows denote very thin axons and 
the white arrowheads denote very thick axons. (E) Mean axonal width was more 
variable in diabetic sedentary mice compared to nondiabetic sedentary mice. Note 
that there are increased numbers of smaller or larger Ia axons in diabetic sedentary 
mice compared to nondiabetic sedentary mice. Diabetic sedentary mice have 
increased variability in axonal width in muscles of individual animals compared to 
nondiabetic sedentary mice (F). (G) Mean inter-rotational distance was also more 
variable in diabetic sedentary mice compared to nondiabetic sedentary mice. 
Diabetic sedentary mice also have increased variability in inter-rotational distance in 
individual muscles compared to nondiabetic sedentary mice (H). CoV is the 
coefficient of variation. Black circles represent 1 muscle, and black lines represent 
the mean CoV in each group (F, H). 
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Table VIII-1. Summary of muscle spindle quantification 
 
A. Axonal Width 
 Mean SEM Minimum Maximum Range Median 
ND-S 
(n=8) 
1.43 0.04 1.06 1.97 0.91 1.36 
ND-E 
(n=8) 
1.68 0.06 1.30 2.28 0.98 1.56 
D-S 
(n=10) 
1.51 0.08 0.93 3.49 2.56 1.39 
D-E 
(n=9) 
1.50 0.07 0.70 2.42 1.72 1.48 
 
B. Inter-Rotational Distance 
 Mean SEM Minimum Maximum Range Median 
ND-S 
(n=8) 
4.34 0.25 1.58 6.43 4.85 4.14 
ND-E 
(n=8) 
4.87 0.30 2.56 8.07 5.51 4.51 
D-S 
(n=10) 
3.86 0.23 1.21 7.46 6.25 3.92 
D-E 
(n=9) 
3.44 0.24 1.18 7.63 6.45 3.38 
 
Summary of muscle spindle quantification for axonal width and inter-rotational 
distance in nondiabetic sedentary (ND-S), nondiabetic exercise (ND-E), diabetic 
sedentary (D-S), and diabetic exercise (D-E) mice. 
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 while the D-S mice had a wide range of widths. This indicates that there is a great 
deal of spread in mean axonal widths for diabetic mice. Furthermore, in order to 
examine the internal variability of muscle spindles within one animal, the coefficient 
of variation was calculated (CoV (%) = (Standard Deviation/Mean)*100). Figure VIII-
5F reveals that the D-S mice had over 3 times more internal variability in axonal 
widths when compared to spindles from ND-S mice (30.7% vs. 9.2%). 
Like axonal width, there was no significant difference between IRD in D-S mice 
(3.86 µm) and ND-S mice (4.34 µm; Table VIII-1). However, D-S mice did have a 
wider range of IRDs compared to ND-S mice (6.25 µm vs. 4.85 µm, respectively; 
Table VIII-1 and Figure VIII-5G). Likewise, when examining the internal variability of 
IRDs in D-S mice, they had 1.5 times greater CoV compared to ND-S mice (Figure 
VIII-5H). These results show that D-S mice have greater variability in their axonal 
width and IRD as a group and within individual muscles. These data confirm our 
previous studies and set the stage to evaluate the results of 4 weeks of low-intensity 
exercise therapy on these mice.  
Nondiabetic mice muscle spindle Ia afferent morphology after exercise. In 
nondiabetic mice, exercise therapy resulted in minimal changes to muscle spindle 
morphology. The mean axonal width of ND-E mice (1.68 µm) was not significantly 
different from that of ND-S mice (1.43 µm; p > 0.05), and the mean IRD of ND-E 
mice (4.87 µm) was also not significantly different from ND-S mice (4.34 µm; p > 
0.05; Table VIII-1). Interestingly, in Figures VIII-6A and -C the histograms of ND-E 
mice have been slightly shifted to the right for both axonal width and IRD when 
compared to ND-S mice. However, the CoVs comparing ND-S and ND-E mice for 
axonal width and IRD are very similar (Figures VIII-6B and -D). These results reveal  
 117 
Figure VIII-6. Ia axonal width and inter-rotational distance in nondiabetic sedentary 
and nondiabetic exercise mice. (A) There was a tight range of mean axonal widths in 
both nondiabetic sedentary and nondiabetic exercise mice. (B) Individual muscles 
from nondiabetic sedentary and nondiabetic exercise mice had similar low variability 
in mean axonal width. (C) There was also a tight range of mean inter-rotational 
distances in nondiabetic sedentary and nondiabetic exercise mice. (D) Individual 
muscles from nondiabetic sedentary and nondiabetic exercise mice had similar low 
variability in mean inter-rotational distance. CoV is the coefficient of variation. Black 
circles represent 1 muscle, and the black lines represent the mean CoV in each 
group (B, D).  
 118 
 
 119 
that exercise therapy in nondiabetic mice led to a slight increase in the axonal widths 
and IRDs of muscle spindles; however, the increase was not great enough to show 
significant increases in the variability of Ia axonal morphology. Therefore, 4 weeks of 
exercise therapy did not significantly affect muscle spindle Ia afferent morphology in 
nondiabetic mice. 
Diabetic mice muscle spindle Ia afferent morphology after exercise. When 
examining the effects of 4 weeks of low-intensity aerobic exercise on diabetic mice, 
there were no differences in mean axonal width in D-E (1.50 µm) versus D-S (1.51 
µm) mice, and no differences in mean IRD between D-E (3.44 µm) and D-S (3.86 
µm) mice (Table VIII-1). When visualizing the histogram, the variability in axonal 
width in D-E animals was no different than the variability in D-S animals (Figure VIII-
7A). Likewise, the CoV was similar in D-E and D-S mice (Figure VIII-7B), suggesting 
that exercise therapy did not alter the Ia innervation in diabetic mice as a group or 
within individual mice. In addition, the variability in IRD was the same between D-S 
and D-E mice (Figure VIII-7C), and the CoV was no different between the two 
groups as well (Figure VIII-7D). These results suggest that exercise did not 
decrease the high variability of diabetic muscle spindle Ia axonal innervation 
patterns. 
 
5. Discussion 
Results from this study reveal that 4 weeks of low-intensity aerobic exercise 
therapy in STZ-induced diabetic C57BL/6 mice repairs sensorimotor deficits without 
altering glucose or insulin levels, body weight, nerve conduction velocities, and,  
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Figure VIII-7. Ia axonal width and inter-rotational distance in diabetic sedentary and 
diabetic exercise mice. (A) There was a similar wide range of mean axonal widths in 
both diabetic sedentary and diabetic exercise mice. (B) Individual muscles from 
diabetic sedentary and diabetic exercise mice had similar high variability in mean 
axonal width. (C) There was also a wide range of mean inter-rotational distances in 
both diabetic sedentary and diabetic exercise mice. (D) Individual muscles from 
diabetic sedentary and diabetic exercise mice had similar high variability in mean 
inter-rotational distance. CoV is the coefficient of variation. Black circles represent 1 
muscle, and the black lines represent the mean CoV in each group (B, D).  
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interestingly, without changing muscle spindle Ia afferent axonal innervation. Based 
on findings from Chapters 2 and 3, diabetic mice with altered sensorimotor function 
display variations in Ia axonal morphology, and 4 weeks of insulin therapy not only 
decreased the behavioral deficits, but also substantially reversed the variability in 
muscle spindle innervation. To our knowledge, no studies to date have used exercise 
therapy to treat large-fiber diabetic neuropathy in a mouse model. In human diabetic 
neuropathy patients, exercise studies are commonly designed to improve the 
symptoms of both small- and large-fiber neuropathy (Balducci et al., 2006; Smith et 
al., 2006). Relating this goal to our current study, the sensorimotor symptoms in 
diabetic mice were improved by exercise; however, not through direct effects on 
muscle spindle afferents.  
Glucose homeostasis. Exercise studies in diabetic humans show mixed results 
in regards to glucose homeostasis. Multiple studies in diabetic and pre-diabetic 
patients involving low-intensity exercise regimens (brisk walking) or exercise 
counseling reported no changes in fasting blood glucose or hemoglobin A1C (HbA1C) 
levels (Balducci et al., 2006; Fritz et al., 2006; Smith et al., 2006; Roumen et al., 
2008). Others have reported that moderate-intensity exercise in diabetic patients 
results in significantly decreased HbA1C, glucose, or glycated albumin levels (Sigal et 
al., 2007; Villa-Caballero et al., 2007; Nojima et al., 2008). Animal research on 
exercise and diabetes has also shown that low-intensity exercise in a type 2 diabetes 
mouse model had no effect on glucose levels (Moien-Afshari et al., 2008). Here, 
blood glucose concentrations in both diabetic and nondiabetic mice were not 
changed by 4 weeks of low-intensity exercise therapy consisting of brisk walking. 
Our results fit well with human and animal studies demonstrating that lower-intensity 
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exercise has little-to-no effect on glucose homeostasis. In addition, we have reported 
no effects of exercise on body weight or blood insulin concentrations in the current 
study, which is expected with a type 1 diabetes model in which the animals typically 
fail to gain weight and have decreased beta cells to produce insulin. Perhaps in type 
2 diabetes obesity models in which insulin production is intact (such as the db/db or 
ob/ob mice), we might have expected changes in weight and insulin levels. 
Nerve conduction velocities. As we have reported in Chapters 2 and 3, STZ-
induced diabetic mice display significantly decreased sciatic motor nerve conduction 
velocities while showing no changes in sensory nerve conduction velocity. The 
current study is consistent with these findings, but demonstrates that low-intensity 
exercise therapy had no effect on deficits in MNCV and did not alter SNCV. This lack 
of effect is in accordance with our results that exercise had no direct effect on 
peripheral nerves. Balducci et al. (2006) completed a 4-year exercise intervention 
study in diabetic patients and found that peroneal MNCV significantly increased in 
the exercise compared to control groups, and found no increase in sural SNCV. 
However, MNCV in exercised patients was not significantly different than controls 
years 1-3 of the study. It is possible that our exercise intervention in diabetic mice 
was not of sufficient duration or intensity to induce electrophysiologic changes in 
peripheral nerves.  
Sensorimotor improvement without action on nerves. The one parameter 
that was significantly improved by exercise therapy was the performance on the 
beam-walk apparatus. Improved sensorimotor function in exercised diabetic mice 
could be due to mechanisms involving many different systems: proprioceptive 
nerves, extrafusal muscle fibers, intrafusal muscle fibers (muscle spindles), 
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vestibular organs, or cutaneous afferents. Most likely, exercise has an effect on a 
combination of the above systems to induce improvements in sensorimotor control. 
As our previous results have showed, insulin treatment resulted in sensorimotor 
repair with concomitant muscle spindle innervation improvements. Therefore, we 
examined the Ia afferent innervation morphology in this study as well; however, Ia 
afferent innervation did not change after exercise therapy in diabetic mice. 
Consequently, our low-intensity 4 week exercise paradigm in STZ-treated diabetic 
mice produced animals with an improvement in sensorimotor behavior without 
directly affecting group Ia proprioceptor morphology. 
Extrafusal fibers and sensorimotor function. One major question brought 
about by the current study is how does low-intensity exercise therapy in STZ-induced 
diabetic mice improve sensorimotor function? Our data suggests these positive 
actions are not through direct effects on muscle spindle proprioceptor innervation, 
which opens the door to other possibilities. Sensorimotor function, particularly based 
on the beam-walk task, is inherently complicated, and muscle spindles are 
completely surrounded by the extrafusal skeletal muscle environment. Extrafusal 
muscle lengthening leads to intrafusal lengthening causing proprioceptors to fire and 
monosynaptically signal to alpha motor neurons. Extrafusal skeletal muscle fibers 
are known to atrophy in the setting of diabetes (Cotter et al., 1989), and it is plausible 
to assume that their damage could lead to muscle spindle dysfunction. Importantly, it 
has been found that exercise after nerve injury can decrease muscle atrophy 
(Goldshmit et al., 2008), and exercise therapy can also increase muscle strength in 
type 2 diabetic patients (Praet et al., 2008). In addition, Richardson et al. (2001) 
performed intervention exercises on peripheral neuropathy patients directed at 
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improving ankle strength. They found that 3 weeks of exercise therapy was 
successful at increasing ankle muscle strength and resulted in improved balance. 
Therefore, it is feasible that exercise therapy can have a directly supportive effect on 
extrafusal muscle fibers, which can compensate for proprioceptive alterations and 
result in improved sensorimotor function.  
Increasing exercise intensity. It is possible that a higher intensity exercise 
training program could lead to improved spindle morphology via decreased Ia 
afferent variability. As mentioned above, human studies utilizing moderate-intensity 
exercise resulted in improved glucose homeostasis (Sigal et al., 2007; Villa-
Caballero et al., 2007; Nojima et al., 2008). Glucose toxicity is implicated as one of 
the primary causes of nerve dysfunction in the setting of diabetes (Duby et al., 2004; 
Tomlinson and Gardiner, 2008). Hyperglycemia leads to high glucose concentrations 
within neurons, which can lead to an increase in reactive oxygen species. 
Interestingly, Nojima et al. (2008) administered a moderate-intensity exercise 
protocol in diabetic patients and found a decrease in urinary 8-hydroxy-2’-
deoxyguanosine, a product of DNA oxidative damage. If increasing exercise intensity 
decreases blood glucose levels and concomitantly oxidative stress, then it might 
result in a more positive impact on peripheral nerves directly.  
Extending exercise duration. Not only could a more intense exercise protocol 
have a greater effect on peripheral nerves, but also could exercise training for a 
longer period of time. Our study consisted of 4 weeks of exercise therapy on the 
treadmill, while other animal exercise studies have varying lengths of exercise 
protocols ranging from 3 days – 7 weeks (Molteni et al., 2004; Ying et al., 2005; 
Moien-Afshari et al, 2008) with different results. Interestingly, only 3 days of voluntary 
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running significantly increased NT-3 mRNA levels in the DRG of rats (Molteni et al., 
2004), but 7 weeks of moderate-intensity exercise was needed to improve 
endothelial function in db/db mice (Moien-Afshari et al., 2008). As mentioned 
previously, Balducci et al. (2006) did not record significant changes in NCV until 4 
years of exercise training in human diabetic patients. Taken together, exercise 
studies have many different outcome measures requiring varied protocols, and 
perhaps with a longer protocol, we may be able to see muscle spindle anatomical 
changes after exercise.  
In conclusion, we have identified a low-intensity exercise paradigm that is 
successful at reversing large-fiber sensorimotor deficits in diabetic mice. This is the 
first study, to our knowledge, that has utilized exercise therapy to treat large-fiber 
DPN in mice. Additionally, we have found that, in concordance with other studies, 
low-intensity exercise therapy does not modify blood glucose concentrations. Future 
studies could address molecular mechanisms by which exercise is improving 
behavior outcomes with the current protocol, and additionally extend the exercise 
paradigm to be of greater intensity and a longer amount of time. This study provides 
an animal model of treatment for large-fiber DPN that will allow for a more 
mechanistic approach to understanding how exercise improves the quality of life in 
diabetic patients. 
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IX. CHAPTER FIVE 
 
Conclusions 
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Overall, the goal of this body of work was to characterize large-fiber diabetic 
sensorimotor polyneuropathy in a widely used animal model of diabetes, and explore 
the hypothesis that the symptoms of large-fiber DPN could be due, in part, to 
aberrant muscle spindle innervation. Through the development of novel techniques 
to visualize muscle spindle afferent innervation morphology, we have discovered 
alterations in diabetic mice that we think may translate to the pathogenesis occurring 
in diabetic humans. However, because visualization of muscle spindles in humans is 
extremely difficult, and only through indirect testing of muscle spindle afferents can 
any information be gained, our experimental paradigm will be of great benefit to 
future understanding and treatment of large-fiber DPN. In addition to characterizing 
large-fiber DPN in diabetic mice, we sought to test two treatments for the repair of 
large-fiber behavioral and anatomical deficits to get a better understanding of the 
pathophysiology taking place in DPN, and to direct future studies.  
 
Chapter Two. Diabetic mice display sensorimotor deficits and altered muscle 
spindle Ia afferent innervation 
This study was the initial characterization of large-fiber neuropathy in STZ-
induced diabetic mice up to 10 weeks post-induction of diabetes and in type 2 
diabetic db/db mice. These data suggest that diabetic mice undergo damage to large 
sensory axons that may contribute to deficits in large-fiber sensory feedback 
associated with balance and gait. Specifically, results from this study demonstrated 
that 1) STZ-induced diabetes leads to sensorimotor deficits involving both balance 
and gait. 2) STZ-induced diabetic mice display slowly progressive motor nerve 
conduction velocity deficits; however sensory nerve changes were not evident in the 
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digital nerve of the hindpaw. 2) Muscle spindle Ia afferent innervation is highly 
variable in diabetic mice, which differs from nondiabetic mice who display consistent 
innervation patterns. 3) Type 2 diabetic db/db mice also have similar alterations in 
their muscle spindle Ia afferent innervation morphology to STZ-induced diabetic 
mice. 
We hypothesize that the altered muscle spindle innervation morphology 
observed in diabetic mice is likely due to varying rates of axonal degeneration and 
subsequent regeneration. It is known that accumulations of neurofilament and other 
neuroproteins can be seen in a degenerating axon, which may be reflective of the 
larger axons we visualized with neurofilament-H immunostaining. In addition, nerves 
that are in the process of regeneration can have multiple thin axonal sprouts, which 
may be indicative of the smaller axons we also visualized with neurofilament-H 
immunostaining. Neurodegeneration/regeneration has been reported in cutaneous 
nerve fibers in DPN, and muscle spindle afferents could be similarly affected. We 
also hypothesize that the alterations in the anatomy of spindle afferents are leading 
to electrophysiologic output disruption of those afferents in diabetic mice, which 
could be resulting in the sensorimotor changes observed in these animals. 
Electrophysiologic output disruption of muscle spindle afferents could result in deep 
tendon hyporeflexia due to the involvement of spindle afferents in the monosynaptic 
reflex arc. Interestingly, patients with diabetic neuropathy have been reported to 
have hyporeflexia and sometimes even areflexia. This could be due to alterations in 
muscle spindle afferents in human patients with DPN similar to the changes seen in 
our diabetic mice.    
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Future studies could examine the cell bodies of proprioceptors to determine if 
changes are visible in the dorsal root ganglion in addition to the axonal terminations 
in skeletal muscle. This could be done using alpha-3 Na/K+ ATPase, a channel that 
has been shown to be selective to muscle spindle proprioceptors and is easily 
visualized in the perikarya of DRG neurons. Co-labeling proprioceptors with 
activating transcription factor 3 (ATF3) would suggest that they muscle spindle 
sensory afferents are damaged from diabetes and increase expression of ATF3 to 
induce regenerative growth. In addition, future studies could be employed that test 
the electrical output of Ia afferents to determine if morphologic alterations do, in fact, 
lead to sensory afferent/motor efferent dysfunction. This could be performed using 
an acute isolated spinal cord preparation that recorded output of motor neurons after 
Ia afferent stimulation. Lastly, we would like to further understand the differences 
and/or similarities between type 1 and type 2 diabetic neuropathies. Our current 
study was limited by only examining the anatomical changes in type 2 diabetic mice, 
and we could further our understanding by examining behavioral and 
electrophysiologic changes in this animal model as well. 
 
Chapter Three. Insulin treatment modifies development of sensorimotor 
deficits and repairs muscle spindle Ia afferent innervation in diabetic mice 
This study was performed to determine whether sensorimotor, 
electrophysiological, and spindle deficits in a large-fiber type 1 diabetes mouse 
model were reversible after treatment with insulin. These data suggest that systemic 
treatment with insulin effectively reversed behavioral and anatomical large-fiber 
neuropathy deficits in mice. Specifically, results from this study demonstrated that 1) 
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sustained insulin release for 4 weeks in STZ-induced diabetic mice decreased blood 
glucose levels, increased body weights, and increased serum insulin concentrations 
to levels higher than nondiabetic mice. 2) Insulin increased motor nerve conduction 
velocity and altered sensory nerve conduction velocity. 3) Insulin decreased 
diabetes-driven pathologic muscle spindle Ia innervation variability. 
Systemically, insulin can decrease glucose toxicity that is hypothesized by many 
to lead to neuropathy. However, others suggest that in a type 1 diabetes model the 
nerves are starved for insulin as a trophic factor, and perhaps giving insulin back to 
those nerves leads to healthier peripheral nerves. We hypothesize that insulin in this 
study was having an effect both systemically and more directly on peripheral nerves 
in order to improve sensorimotor behavior and spindle morphology. Interestingly, 
insulin is prescribed for human patients with diabetes, and yet these patients can still 
develop DPN. We think this may be decreasing the glucose toxicity in these patients; 
however, it may not be at high enough concentrations to be affecting the nerves 
directly. Perhaps giving intrathecal injections or near-nerve injections of insulin would 
lead to a decrease in the prevalence of DPN.  
Future studies could deliver insulin intrathecally or directly to the sciatic nerve in 
order to tease out the effects of insulin being due to either decreasing hyperglycemia 
or due to a direct trophic effect on nerves. In addition, insulin signaling could be 
examined in specifically in proprioceptors to understand if downstream signaling 
pathways are disrupted after STZ-treatment.  
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Chapter Four. Aerobic exercise therapy improves sensorimotor deficits and 
has no effect on variability in muscle spindle Ia afferent innervation in diabetic 
mice. 
This study was undertaken to examine the effects of exercise therapy on the 
symptoms of large-fiber DPN and muscle spindle morphologic variations. These data 
suggest that low-intensity aerobic exercise therapy improved sensorimotor deficits; 
however, without having an effect on large nerve fiber innervation of muscle 
spindles. Specifically, results from this study demonstrated that 1) 4 weeks of low-
intensity aerobic exercise therapy repaired beam-walk performance without altering 
glucose or insulin levels or body weight. 2) Exercise therapy had no effect on motor 
or sensory nerve conduction velocity. 3) Exercise therapy had no effect on the high 
variability of Ia afferent axonal morphology.  
We hypothesize that the improvement in sensorimotor function in diabetic mice 
after exercise is due to multiple factors. Although not measured in this body of work, 
improvements in extrafusal fiber strength and/or decreased atrophy of extrafusal 
fibers may have contributed to the repaired balance of diabetic mice. In addition, 
exercise is known to increase blood flow and have a positive effect on the 
vasculature, which is damaged in the setting of diabetes. Therefore, improvements in 
vascular flow could also have contributed to sensorimotor repair. These findings also 
suggest that the beam-walk task is reflective of measures other than spindle 
innervation, which need to be taken into consideration when examining the results of 
this behavioral task.  
Future studies could examine the molecular mechanisms by which exercise 
improved large-fiber behavioral abnormalities. These studies could focus on 
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exercise’s effect on extrafusal fibers, vascular flow, oxidative stress, and/or 
cutaneous innervation. In addition, a more intense and perhaps longer duration of 
exercise therapy in the same animals might be robust enough to induce spindle 
improvements.  
 
Collectively, these studies demonstrate that STZ-induced diabetic mice are an 
excellent model of large-fiber diabetic sensorimotor polyneuropathy. Although 
behavioral changes in large-fiber DPN are subtle, they can be measured through the 
beam-walk task and, we hypothesize, through gait analysis, at 10 weeks post-STZ 
injection. Importantly, these behavioral changes may be due to altered muscle 
spindle Ia afferent innervation patterns, which could lead to aberrant spindle output. 
Insulin treatment repairs both behavioral and anatomical changes, while exercise 
therapy only has an effect on the sensorimotor behavior task. These studies give 
insight into human large-fiber DPN, and will hopefully be a stepping-stone from which 
future studies can discover the molecular mechanisms at play in both the mouse 
model and eventually in human patients. With understanding of the mechanisms, 
comes hope for better and more sophisticated treatments, which are currently 
lacking in the area of DPN. In addition, these studies also add to the body of 
literature on muscle spindles and their innervation and function, which will hopefully 
be applied to other diseases in which patients have difficulty with balance and gait 
that could be attributed to spindle dysfunction, such as Charcot-Marie-Tooth disease, 
myasthenia gravis, and Duchenne muscular dystrophy.  
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